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Counterfeit drugs are non-authentic drugs that have been manufactured using incorrect 
amounts or incorrect ingredients to either reduce or nullify the potency of the drugs. Trading 
and use of counterfeit drugs have been reported by WHO(World Health Organization) as one 
of the causes of high morbidity, mortality in the Nigerian health sector. This study aims to 
identify the impact of NAFDAC on drug quality control in Nigeria. A cross-sectional survey 
of 37 participants, including medical professionals, NAFDAC staff, pharmacists and 
consumers was done using a questionnaire. Results from the study revealed that the drug 
situation in Nigeria is not good and that the high cost of good quality drugs, inadequate laws 
or poor enforcement of the existing drug quality control regulations and the inadequate drug 
distribution monitoring system were the major factors influencing the production and 
distribution of low-quality drugs in Nigeria. NAFDAC has set up enforcement officers for 
control and routine inspection, providing mobile authentication of services to help consumers 
differentiate fake from original drugs to combat this issue. In conclusion, NAFDAC is trying 
its best to combat the drug issues in Nigeria but more efforts are needed to make it effective. 
This study recommends that the government should subsidise the cost of drugs, put up more 
stringent drug laws and punishment for defaulters to discourage production and distribution 
of counterfeit drugs in Nigeria. 
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1.1 Background of the Study 
Trading and use of substandard and counterfeit drugs have been reported by WHO as one of 
the causes of high morbidity, mortality, and lack of public confidence in the health sector 
worldwide. 
Reports suggest that substandard and counterfeit drugs have had side effects on users, ranging 
from injury, complications, paralysis, disability and treatment failure, and in some cases even 
death (WHO 2006). 
Fake and substandard drugs are non-authentic drugs: that are manufactured using incorrect 
amounts of ingredients, and subsequently reducing the potency of the drugs. Fake and 
substandard drugs or "counterfeit drugs" was described by the World Health Organization as 
"a medicine intentionally and fraudulently mislabelled with respect to identity and/or source”. 
Counterfeiting may refer to both branded and generic products, and counterfeit products can 
include items with the right ingredients or the wrong ingredients, with insufficient active 
ingredients, or with fake packaging "(WHO 2006). Thus, drug counterfeiting has been 
identified as a serious public health issue that has taken on global dimensions and is gaining 
ground rapidly daily with many new cases reported (Akinyandenu 2013). However, 
worldwide it has been noted that counterfeit drugs are an organized crime that gives a lot of 
profit to criminals. According to a survey, "in many parts of the world, criminals have 
discovered that drug counterfeiting is lucrative financially and of relatively low risk. As a 
result, organized crime has moved from drug smuggling and arms handling to drug 
counterfeiting "(Akunyili 2005). 
In general, counterfeiting of drugs has been reported to impact various countries in different 
ways. Data on global and regional counterfeiting incidence are highly misleading  because 
they are underreported or they have not been revised. Therefore, what is collected as data is 
pure estimates of the crime. Factsheet (2013) made this argument clearly, claiming that: 
counterfeiting of medical goods and related crimes impact all countries, whether as countries 
of origin, transit, or marketplace.  
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Recent figures indicate that global sales of counterfeit drugs are worth more than €57 billion, 
having doubled between 2005 and 2010, in just five years.  
Counterfeit  medicines have become a serious problem for developed countries, with a 
calculated effect on lives. For example, 200,000 of the one million deaths from malaria that 
occur each year worldwide are probably the product of counterfeit anti-malaria drugs 
(Karunamoorthi 2014).  
However, a current meta-analysis by Ozawa et al. (2018) revealed a high prevalence of 
13.6% of substandard and counterfeit drugs in underdeveloped countries. Also, WHO made 
an estimate of about 10% of medical products in underdeveloped countries to be of low 
standard and falsified, which gives a lot of burden to the health systems, destroys the 
confidence, and increases the illness, morbidity, and mortality risk. It suggests that 700,000 
Africans die each year from the use of bogus antimalarial or tuberculosis drugs (Akinyandenu 
2013). Nigeria has been reported to have one of the highest incidences of low standard and 
fake drugs in Sub-Saharan Africa (Spink et al., 2016). There have also been so many reports 
of deaths as a result of the consumption of low standard and fake drugs in Nigeria 
(Akinyandenu 2013).  
Over recent years, these high instances of counterfeit medicines around the globe have given 
rise to the anti-counterfeiting epoch that dovetails the fight against the hazard. The war is 
gathering traction globally and the anti-counterfeiting regulatory agencies are engaged in a 
whirlwind of activities and initiatives to curb the threat. In 2006, the World Health 
Organization (WHO) launched a global policy on drugs of low quality, with a specific 
emphasis on the African countries (WHO 2007). The UN Office on Drugs and Crime 
(UNODC) followed suit in 2010 and for the first time identified illicit drugs as a major 
concern in its Global Crime Threat Assessment alongside cocaine trafficking, maritime 
piracy, and trafficking in human beings (WHO 2013). Three years later Interpol also joined 
these efforts by signing a landmark pharmaceutical company’s agreement to expand its fight 
against so-called pharmaceutical crime (Interpol 2014). In the last 17 years, the issue of fake 
pharmaceuticals has become a major concern for international cooperation in health and law 
enforcement, as well as in national policy debates, especially in the global South. 
However, Nigeria is not left out of this move and has set up a regulatory agency the National 
Agency for the Administration and Control of Food and Drugs (NAFDAC), which was at the 
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forefront of the war. The Federal Government of Nigeria created NAFDAC in 1993 with the 
task of safeguarding the nation's health by providing effective regulation of the economy's 
food, drug, and chemical industry. One of the agency's goals was to make sufficient supplies 
of drugs that are reliable, secured, accessible, and of good quality available to the Nigerian 
population at all times. The death of 150 children due to error in the formulation of drug 
syrup ‘My Pikin’ triggered the introduction of this agency in Nigeria (NAFDAC 2017). 
According to Keris (2004), the agency has the function of ensuring that all products 
registered by it meet the standards acceptable with respect to quality and efficiency.  
One of the measures which is adopted by NAFDAC to control the production of fake drugs is 
drug registration of medicinal products that comes into Nigeria.  
Drug registration by NAFDAC is the process of ensuring that adulterated or fake drugs are 
not allowed into the Nigerian drug market. WHO (2002) defined a fake drug as one which is 
mislabelled intentionally or fraudulently with respect to the source and/or identity. WHO 
stated that fake drugs are: 
a. any drug or drug products which are so coated, coloured, polished or powdered in 
such a way that the damage is hidden, or which is made to look better or of higher 
therapeutic value than it actually is;  
b. any drug or drug product in which the container is formed, made, or filled in such a 
way as to be misleading.  
c. any drug or drug product in which the label does not have an appropriate direction for 
use or adequate caution against use under the conditions listed below :  
1. A certain pathological conditions that are contraindicated. 
2. Adequate usage dose for children. 
3. Usage dosage for adults. 
4. Certain methods for the duration of use.  
5. Side effects of the drug. 
 
Apart from the above measures, there are so many other roles/measures adopted by 
NAFDAC to improve the quality of drugs produced in Nigeria.  
Therefore, this study seeks to find out the various roles/measure which NAFDAC has taken 
to improve the quality of drugs produced and distributed in Nigeria. 
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The International Council for Harmonisation of Technical Requirements for Pharmaceuticals 
for human use (ICH) is an effort bringing together regulatory authorities and the 
pharmaceutical industry to address the scientific and technological aspects of producing and 
registering pharmaceutical products. ICH put up guidelines and criteria for the registration of 
pharmaceutical products with the aim of fostering public health. These guidelines include 
quality, safety, efficacy, and multidisciplinary guidelines. They help to address and decide on 
the scientific issues resulting from drug registration and curtail the production and 
distribution of fake drugs around the world. The ICH guidelines are being used by mostly the 
European countries, the Japanese, and the United States. Some other countries who are 
members of and use the ICH guidelines include Brazil, Singapore, Canada, Republic of 
Korea, China, and Switzerland, etc. Some of the ICH observers include World Health 
Organisation (WHO), Therapeutic Goods Administration (TGA), Australia; South African 
Health Product Regulatory Authority (SAHPRA), South Africa; and many more (Brennan 
2015).  
However, NAFDAC is not among the members or observers of the ICH, and so, not regulated 
or affected by its guidelines.  
Nigeria does not use the ICH guidelines, due to the fact that ICH was made to regulate the 
activities of the European, Japanese and United States, NAFDAC does not use their guideline 
as these guidelines were built around the activities of these countries. 
 
1.2 Statement of the Problem 
The issue of Low and wrong quality drug production in Nigeria has negatively affected the 
healthcare system and has brought about very harmful or even deadly effects on the 
consumers, leading to illness, temporary or permanent disability or even death and any 
individual can be affected (Akinyandenu, 2013; Foreman 2014, Iwokwagh 2013). For 
example, 'the use of counterfeit anti-malarial drugs alone takes the lives of over 700,000 
Humans annually' (NAFDAC 2017). Scholars such as Osibo (1998) and Bamitale (2013) 
noted that Nigeria has more fake or counterfeit drugs in circulation than legitimate drugs. 
Lambo (2006) recorded that in 1990, 54 percent of drugs were fake at every major pharmacy 
in Lagos and that the figure rose to 80 percent in the following year. Spink et al. (2016), 
reported that Nigeria has one of the incidences of low quality and fake drugs in Sub-Saharan 
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Africa and there have also been so many reports of deaths as a result of consuming low 
standard and fake drugs in Nigeria (Akinyandenu 2013). 
According to the World Health Organisation (2007), the prevalence of fake drugs is higher in 
countries with poor controls, compliance, and supply shortages of essential drugs, 
unregulated markets, and costs that are not affordable. Because of this, the price, safety, and 
effectiveness of drug products cannot be guaranteed, especially in developing countries. Fake 
drug dealers and their associates are constantly attempting to escape detection, and also 
disguising their activities. Fake drug manufacturing does not need to take place in vast 
infrastructures or laboratories but in ordinary homes, small cottage industries or in backyards. 
The high demand for drugs and low manufacturing costs are causing counterfeiters to 
continue because there is a shortage of effective drug-deterrent legislation. The high cost of 
medicines makes way for consumers to purchase medicines outside of the normal supply 
chain, particularly the poor. Poverty and the poor distribution network of drugs are major 
factors that create a market for fake circulation of drugs. The weakest point in drug control is 
possible in the field of implementation and compliance, according to the NAFDAC Director-
General. The country's harsh socio-political interplay over thirty years has also brought some 
constraints and led to the weakening of drug control in Nigeria, leading to the faking and 
dumping of drug products across disorderly channels of drug distribution (NAFDAC 
customer bulletin 2003). 
Drug trafficking by unskilled dealers is a popular phenomenon in the developing world. Such 
drug dealers are also the first point of healthcare contact by customers who support them for 
reasons such as ease, supply reliability, and inexpensive quality. The explanation is that most 
of the time customers don't find drugs in government clinics and the pharmacies licensed are 
often far and costly. The failure of patients to assess the quality of the drugs they are taking is 
a significant public health issue as these drugs can be ineffective and dangerous (Dhikav 
2003). Fake drugs have the potential to deceive, particularly when replicated to make it look 
like the original product so consumers are unlikely to be suspicious. For a fact, the 
mechanism by which patients receive their medications is distinct from that for most 
consumer goods: they are administered by physicians or health care staff. Also if patients 
select their own drugs, they will lack the advanced expertise to detect if the drug they are 
buying is of good quality, let alone being able to detect whether or not the medication is fake 
(WHO 2007).  
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The high incidence of fake drugs in Nigeria is a result of the haphazard ways in which an 
import license on drugs was given in the 1980s to everyone by politicians and military 
leaders at the time, irrespective of the actual public health implications of their actions. In 
Nigeria, the epidemic of fake drugs has been a very big issue over the past two decades. Fake 
medications have proved to be a significant factor in leading to high mortality rates. The 
problem of fake drugs was so serious that the selling of drugs made in Nigeria was officially 
banned by neighbouring countries including Ghana and Sierra Leone. Not only did the 
problem of fake drugs end there, but it went to the point where drugs were hawked even in 
commercial buses. All of those things have affected Nigeria as a whole. On the one hand, 
with the launch of the "new NAFDAC" in April 2001, some accomplishments were achieved 
which caused a reduction in the problems (NAFDAC consumer bulletin, 2003).  
The negligence of the dysfunctional judicial system and widespread corruption are major 
reasons why fake drugs are easy to manufacture and sell. Indiscretion in the system helps 
counterfeit drug manufacturers to sell their drugs cheaply to chemists who then sell to 
customers. As a result, the ultimate damage is seized up to not only the patients who are 
being treated by counterfeit medicine but also affects the credibility of the doctor who was 
treating patients, as well as giving a bad image to the health system (Dhikav 2003).   
The cost of purchasing drugs is very high, making it very difficult to obtain the drug (Lambo 
2006). The unorganised and poorly monitored drug distribution network with several illegal 
shops help in the rise of fake drugs (WHO 2006). 
Due to the problems stated above, there is a need for individuals to understand the control 
measures which have been put in place to improve drug quality production and prevent 
individuals in the country from falling a victim of consuming low quality or fake drugs. 








1.3 Purpose of the Study 
The purpose of this study is to evaluate the impact of NAFDAC on the improvement of drug 
quality in Nigeria. 
1.4  Research Objectives 
2. To understand the perception of various group of individuals in Nigeria about the 
drugs produced/consumed in the country 
3. To find out the preferred type of drugs (locally produced or foreign) bought by 
consumers or prescribed by medical practitioners in Nigeria. 
4. To identify the major contributing factors to the production and distribution of low-
quality drugs in Nigeria 
5. To identify the control measures used by NAFDAC in ensuring the production of 
good quality drugs 
6. To determine the degree to which the objective of drug quality improvement has been 
achieved in Nigeria. 
 
1.5 Research Questions 
2. What are the perceptions of Populations in Nigeria about the drugs 
produced/consumed in the country? 
3. What type of drugs (locally produced or foreign) do Consumers/Customers prefer to 
use/prescribe/buy?   
4. What are the major contributing factors that affect the production, distribution and 
consumption of low-quality drugs in Nigeria? 
5. What control measures have been put up by NAFDAC to influence and improve the 
quality of drug production and consumption in Nigeria? 
6. To what extent have NAFDAC achieved its objectives of drug quality improvement in 
Nigeria? 
1.6 Scope/Delimitation of the Study 
This study will cut across the impact of NAFDAC on the quality of medicinal products that 
are produced/consumed in Nigeria.  
It will focus on health professionals, professionals in the drug-production industries as well as 
NAFDAC members and consumers across Nigeria. 
17 
 
1.7 Outline of the Thesis 
The structure of the thesis is as follows: The thesis is divided into six chapters.  
Chapter one introduced the research subject topic, explained the reason for and aim of the 
study as well as the significance of the study to the health and research world.  
Chapter two, which is named the literature review is divided into two parts; the first part 
started by explaining the important concepts of drugs and drug quality, the drug situation in 
Nigeria as well as NAFDAC and its functions in battling fake drugs. The second section 
reviewed various works of literature on different works related to the study as these would 
help broaden the readers’ knowledge of what is needed for a good understanding of the study.  
Chapter three is termed the research methodology. In this chapter, the researcher explained 
the suitable methods and designs used in conducting the study which would help meet the 
research goals and address the research questions. 
Chapter four reveals the results of the analysed data. It reports the individual responses to the 
different questions and analyses them. 
Chapter five is the discussion. It discussed the entire work by discussing the results of the 
study and relating them to the findings from other related studies and how it addressed the 
research questions, it also summarizes the entire findings from the study, gave 
recommendations for further studies, and finally concluded the work. 
1.8 Significance of the study 
This study will be of great benefit to all drug users most importantly the consumers, as the 
number of individuals who tend to seek medical attention / treatment outside the country will 
be rest assured that drug products and services are of good quality in the healthcare system in 
Nigeria.  
It will also help to boost the country’s confidence and economy standards in the Nigerian 
pharmaceutical companies as long as they comply to the terms of NAFDAC, they will have 
customers to patronize them.  
It would also add to the existing works of literature on drug quality and serve as reference 
material to the research students. 
18 
 
                                                       CHAPTER TWO 
LITERATURE REVIEW 
2.1 The Concept of Drug Quality 
Medicinal products are important components of the health sector worldwide and also they 
are very vital to consumers, as they play an important role in patient management and in the 
pharmaceutical sector. Patients, caregivers, physicians, and the communities have hope that 
drugs being prescribed and consumed are of good quality and authentic and also meet the 
right standard.   
Drug product quality is said to be how suitable a drug substance or product is for its intended 
use (International Conference of Harmonization). It involves how strong and pure the drug 
substance is, the process of manufacturing as well as its supervision. The issue of drug 
quality is mainly associated with fake and counterfeit medicines, which is seen mainly in 
developing countries (Ebenezer 2015). For instance, WHO received 771 confidential and 
public reports regarding counterfeit drugs between 1982 and 1999. About 80% of the 
reported were from the developing countries whereas the rest of the 20% came from wealthy 
countries (Ebenezer 2015). The prevalence of low-quality drugs was as well reported to be 
high in Nigeria and Thailand as well as Myanmar and Vietnam (WHO 1999). However, the 
Nigerian Government has founded the National Agency for Food, Drug Administration and 
Control (NAFDAC) to aid in the regulation of both local and foreign manufacturers of 
regulated products to help ensure that high-quality drugs are constantly produced, and also 
that they meet both the national and international standards. 
2.1.2 Fake/Counterfeit Drugs  
The definition of fake or counterfeit drugs differs from country to country (World Health 
Organisation, 2013) although the WHO Member States seem to share a similar definition. 
They emphasize deliberate and fraudulent mislabelling of drugs with respect to brand and 
generic products as the defining indices of fake drugs. In this sense, counterfeit products 
include products with correct or wrong ingredients, with or without active ingredients, 
inadequate quantities of ingredient(s), and with fake packaging.  
Similarly, Agbaraji et al. (2012) defined counterfeited drugs as those drugs that are not fake 
and have been manufactured using inaccurate quantities, or inaccurate ingredients, to either 
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lessen the potency, or quash the potency of drugs altogether, and the same is applicable to 
food counterfeit. Therefore, counterfeit or fake drugs simply refer to drugs that are produced 
and sold in forms that deceptively represent their origin, contents, and authenticity or 
effectiveness. 
World Health Organisation (2017) made a classification of counterfeit drugs. These 
classifications are; 
1. Substandard medical products  
These are medical products that do not meet their quality standards and are often referred to 
as “out of specification” products. 
2. Unregistered/unlicensed medical products  
These are medical products that are yet to undergo an evaluation and/or approval by the 
NRRA for marketing/distribution or use. The national/regional regulatory authority may or 
may not have issued the relevant authorization. 
3. Counterfeit medical products  
Counterfeit medical products are products that consciously/deceitfully falsify its identity, 
composition, or source. Such conscious/fraudulent misrepresentation includes any 
substitution, adulteration, reproduction of a certified medical product, or the manufacture of a 





Fig 2.1            Classification of medical products to be used by WHO global surveillance and 
monitoring system and the Member State mechanism (WHO 2017) 
 
2.2 Quality Control 
Quality refers to a set of product characteristics that fulfill consumer expectations and adhere 
to the desired specifications. Quality control (QC) is the mechanism that ensures a produced 
product meets a set of standards and specifications for quality. The ISO 9000 addresses 
various aspects of quality management and establishes quality standards that serve as 
guidelines and tools for businesses who want to ensure consistency in the quality of the 
produced goods (Costigliola, et al. 2017) According to Juran and Godfrey (1999), three key 
tasks are required in order to achieve quality in a manufactured product. They are: 
• Quality planning;  
• Quality control;  
• Enhancement of the standard. 
Planning is reffered to the identification of quality targets, customer needs, and the 
implementation of appropriate manufacturing and control processes to meet the quality 
requirements demanded. Control refers to measuring the efficiency of the production process 
against quality targets. Quality improvement is the mechanism that establishes new high-
quality standards criteria and procedures. 
The quality assurance unit establishes and strengthens specific analytical methods for the 
processing of chemical compounds in drug production. Analytical chemistry is a science of 
measurement that develops and uses methods for the quantitative and qualitative study. A 
specific analytical method must be designed to recognize and measure matter, provided a 
certain compound. The method of identification is also called qualitative analysis. Any time 
there is a need to measure the mass or the concentration of a particular compound a 
quantitative analysis is performed (Costigliola et al. 2017) 
2.3 The National Agency for Food, Drug Administration, and Control in Nigeria 
(NAFDAC). 
NAFDAC, which is the acronym for the National Agency for Food, Drug Administration and 
Control, is an agency under the oversight of the Federal Ministry of Health under the 
Nigerian government. NAFDAC was established in 1993 by means of supporting legislation 
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approved in Decree No. 15 of 1993 and, on 1 January 1994, NAFDAC was formally 
established as a parastatal of the Federal Ministry of Health' to replace an earlier body of the 
Federal Ministry of Health–the Directorate of Food and Drug Administration and Control, 
which had been deemed ineffective, partially due to a lack of such legislation. NAFDAC 
currently headquartered in Abuja (Nigeria's FCT) is headed by Paul Orhii as the Director-
General, who holds a Ph.D. in medicine. NAFDAC has the responsibility of regulation and 
control of the manufacture, import, export, advertisement, distribution, sales and use of food, 
drugs, cosmetics, medical devices, chemicals and packaged water (referred to as controlled 
products) (NAFDAC 2017) 
The 1988 world health assembly influenced NAFDAC development, In that year, the 
resolution of the assembly called on countries to help in the fight against global health threat 
orchestrated by counterfeit/fake pharmaceuticals. 
2.3.1 Structure and Functions of NAFDAC 
Apart from the Director-General, NAFDAC has a board of governors that is not headed by a 
chairman. This chairman is not the director-general but a person appointed by the Nigerian 
president as recommended by the Hon. Minister of Health. The chairman presides over a 
board of governors whose membership includes: 
• Permanent Secretary to the Ministry of Health 
• Director-General of NAFDAC 
• Standard Organization of Nigeria (SON) 
• National Institute for Pharmaceutical Research and Development (NIPRD) 
• President of the Pharmacists’ Council of Nigeria (PCN)  
• Chairman of the National Drug Law Enforcement Agency (NDLEA)  
• Member of each of the Pharmaceutical and Food and Beverage Group of the 
Manufacturers’ Association of Nigeria; 
• Three people included from the general public 
2.3.2 NAFDAC is sub-divided into directorates for the correct and effective division of 
labour and resources. They are: 
• Human Resource Management (HRM) 
• Finance & Accounting (F&A) 
• Research & Statistical Planning (PRS)  
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• Registration & Regulatory Affairs (R&R) 
• Laboratory Services (LS) 
• Ports Inspection (PID) 
• Compliance 
• Food Safety & Applied Nutrition (FSAN)  
• Drug Evaluation & Analysis (DER) 
• Chemical Evaluation & Research (CER)  
• Pharmacovigilance & Post Marketing Surveillance (PV-PMS) 
• Veterinary Medicine & Allied Products (VMAP)  
• Special Duties (SD) 
• Narcotics & Controlled Substances (NCS)  
Some prominent units are: 
• Legal Unit–responsible for providing legal advice on' employee-employer 
relationship laws and is the custodian of legal documents and all Agency agreements. 
• Public Relations Unit–headed by the Office of the Director-General. Its main function 
is to inform, sensitize, educate, and raise awareness about the Agency's position. 
• Internal Audit Division –provides a means to measure the effectiveness of the internal 
control and accounting system, and performs special inquiries. 
2.3.3 The Role of NAFDAC Include:  
• Regulate and monitor the import, export, manufacture, marketing, distribution, selling 
and use of medicinal products, cosmetics, medical devices, bottled water, and 
chemicals 
• Perform adequate tests and ensure compliance with minimum requirements developed 
and authorized by the Council for the successful quality control of food, medicines, 
cosmetics, medical devices, bottled water, and chemical products 
• Ensure adequate inspection of the manufacturing sites and raw materials for food, 
medicines, cosmetics, medical devices, bottled water and chemicals and develop an 




• Inspect imported foods, medicines, cosmetics, medical devices, bottled water and 
chemicals and develop an acceptable quality assurance program including 
certification of manufacturing sites and controlled products; 
• Compile uniform requirements, legislation, and instructions for the manufacture, 
import, export, sale, and distribution of food, drugs, cosmetics, medical devices, 
bottled water and chemicals  
• Register food, drugs, medical devices, bottled water and chemicals 
• Export control and quality inspection of food, drugs, medical devices, bottled water 
and chemicals 
• Establish and maintain related laboratories or other institutions in Nigeria's strategic 
areas as may be necessary to carry out its functions. 
The restructuring of NAFDAC by the administration of Olusegun Obasanjo (former Nigerian 
president) (when the previous board was disbanded in August 2000 and the creation of a new 
board headed by Prof. Mrs. Dora Akunyili (Late) as new director-general in April 2001) 
brought a milestone achievement in Nigeria as a lot of food and drugs were destroyed 
throughout the country, especially on the Onitsha drug market. NAFDAC has registered 
many other accomplishments since its inception until the date (NAFDAC 2017). 
 
2.4 Study of the Drug situation in Nigeria  
With a population of approximately 167 million Nigeria represents a wide drug market. 
Whatever happens in the pharmaceutical market in Nigeria affects medicinal products that 
circulate on the ECOWAS(Economic Community of West Africa) such as this countries 
Nigeria, Ivory Coast, Senegal, Togo, Liberia, Ghana, Republic of Benin etc their markets. 
"The Nigerian industry potentially has the capacity to meet 50-75 percent of the drug needs 
of the country. But the actual production is below 30 percent, so 70 percent of all drugs are 
imported into the Nigerian market." (Okoli, 2000). Bah-Traore (2012) stated in his study that 
the National Agency for the Administration and Control of Food and Drugs (NAFDAC) in 
Nigeria has expanded the scope of counterfeit drugs to include products without the full name 
and address of manufacturers, products labeled "For Export Only", Expired and relabelled 
products designed to prolong their shelf-life, products containing controlled substances and 
medicines not registered with NAFDAC. NAFDAC focuses too much on registration and too 
little on control of the distribution system.   
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In 1968, fake drugs were first found in Nigeria as the situation worsened, and in 2001 Nigeria 
was ranked as the country with the highest incidence of fake drugs. Prior to the Akunyili’s 
era, drug regulatory officers abused their status to rip off money from honest manufacturers 
while taking bribes from counterfeiters to allow access into the Nigerian medicines market 
Akunyili (2005). This encouraged counterfeit drug manufacturing and distribution in Nigeria 
as a stock-in-trade, this led to the ranking of Nigeria as the country with the highest incident 
of fake drugs. Akunyili (2005) reported that drug counterfeiting was first brought to light in 
Nigeria as early as 1968, “So people have been dying in this country from the effect of fake 
drugs since the early 1970s” (Akunyili, 2005). In 1995, Nigeria supposedly provided 88 000 
doses of meningitis vaccine to its neighbouring country Niger, before it was realized that 
these vaccines were fake, about 60000 people had been “inoculated”. Akunyili reported that 
when she assumed office in 2001 as the NAFDAC Boss, counterfeit drugs were widely 
circulating in Nigeria. 
In 2001 an analyses was carried out on  the quality of drugs from pharmacies in Nigeria, it 
showed that around half of the formulations had concentrations beyond the upper and lower 
limits of the standard pharmacopeia in the area they came from. Made-in-Nigeria products 
have also been banned in many West African nations (Bah-Traore 2012). 
The problem of fake drugs and others takes on a new aspect as to who is responsible for 
averting the crisis, or not.  In India, which is a big exporter of medicines to Nigeria, 
NAFDAC has named analysts who are now certifying drugs before they leave India for 
Nigeria. Nigerian medicine agency now allows importers to provide compulsory pre-
shipment details for imported goods from all countries. The Agency (NAFDAC) also held a 
summit with the Indian authorities to raise awareness and encourage them to support Nigeria 
by stopping exports of low standard drugs to the country. It held another one in conjunction 
with House committee on Health with ambassadors of the countries described as the source 
of the influx of fake drugs to the country including India, Indonesia, China, Pakistan, and 
Egypt; a consensus was reached that they would support Nigeria in addressing the problem. 
 
2.5 The Chain of Drug Distribution in Nigeria 
According to the study by Bah-Traore (2012), the drug distribution network in Nigeria is in a 
state of confusion because it consists of free markets, patent medication shops, and 
community pharmacies run by NGOs (Non-Governmental Organizations), private and public 
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hospitals, wholesalers/importers, and pharmaceutical companies. The only products allowed 
to be marketed by vendors are drugs sold Over the Counter (OTC), but they usually sell all 
kinds of drugs as determined by their financial ability. Many have taken the pharmacy 
profession for granted as if no skills and training are needed before a person becomes a 
pharmacist. Patients tend to go directly to market[s] than pharmacies so they can get cheaper 
rates and, in effect, the medicines they often purchase are fake, obsolete, or of low quality. 
These types of episodes occur on a regular basis and patients do not know because they are 
after cheaper drugs (due to socioeconomic conditions of countries), but they are cheated with 
either expired or fraudulent drugs in most cases. To maximize their profits pharmaceutical 
companies tend to sell their drugs across unregulated markets rather than using approved 
routes like hospitals or pharmacies. Thus the drugs will end up in the hands of unqualified 
individuals (Bah-Traore 2012). 
It is a popular scene in Nigeria to see medicinal product traders selling, among other things, 
cigarettes, kola nuts, and oranges in market kiosks, car parking wards, and roadsides hawking 
drugs ranging from over the counter products to antibiotics. The drugs are typically left under 
the sun under such conditions that the active ingredients may deteriorate. 
Therefore, NAFDAC has implemented ongoing surveillance at all sales outlets.   Lists of 
known counterfeit/substandard drugs are regularly published in Nigerian newspapers and 
medical reviews. The World Health Organization (WHO) has agreed with NAFDAC's 
proposal to conduct a Pan-Nigerian survey to assess the extent of the goods in circulation that 
are not standard. New measures have been placed in place to ensure safe medicines are 
imported into Nigeria; these are: 
• NAFDAC inspectors must inspect the manufacturing plants in the exporting country 
before registration or renewal of registration for any drug. In the case of medicines, to 
ensure good manufacturing practice, the factory must be' WHO approved. 
• In the future, before drugs are imported into Nigeria even after registration, NAFDAC 
approved analysts will perform a pre-shipment review of the drugs in the respective 
countries (Bah-Traore, 2012). 
2.6 Extent of Poor Quality Medicine in Nigeria 
Many studies conducted in developing countries to assess the prevalence of counterfeiting 
medicines indicate that approximately half of the drugs examined were under the standard. 
26 
 
Similar findings appeared to have been obtained in selected African countries (Tanzania, 
Burkinafaso, Uganda, Angola, Burundi, Zimbabwe, Rwanda, Ghana, Mali, Botswana, Sudan, 
Mozambique, Congo, Cameroon, and Kenya). Kibwage et al. (1992) and Roy (1994) reported  
in  former studies back in Kenya, approximately 77 percent of the various drug samples 
collected from the country were inferior. In recent studies, it is shown   that approximately 40 
percent of the medicinal products tested failed the quality assays (Amin et al. 2005). 
The study conducted to assess the occurrence of non-standard medicinal products was report 
by Atemnkeng et al. (2006), who found out that the Republic of Congo had approximately 
37.5 percent of antimalarials (artemisinin derivatives) that were randomly from pharmacies  
and quality testing of active ingredients was failed in Kenya.  
These studies showed that medicinal products are of low quality in Africa; and nearly half of 
the samples collected in this area showing the failure of the necessary tests.  This studies are 
similar to the findings of low-quality drugs in Nigeria, of  which in most studies ranges from 
about 32 percent to 48 percent. Bate et al. (2009)'s study showed a smaller proportion (18 
percent) fails the standard tests which is not accepted as it can’t underestimate the dangers 
that may result from it. This decrease reported from Bate et al. (2009) can be due to the 
methods used to assess the medicines ' chemical constituent of the small sample size (140 
treatment packs). An analysis by Bate and Hess (2010) displayed that general failure rates in 
Lagos dropped from around 32 percent in 2007 to around 13 percent in 2010. 
However, studies shows that a small amount of sample sizes involved in 2007 and 2010 may 
have lead to the above  and is not conclusive to observations from larger studies..  
According to WHO (2011) the largest number of  antimalarial samples failed of about (63.9 
percent) is from Nigeria. His findings again may have been narrowed to the small sample size 
used in this study. Research by Taylor et al. (2001) showing that 48 percent of Nigeria's 
randomly sampled drugs (antibiotics and antiparasitics) did not meet the specified 
pharmacopeia requirements appeared to be the first to use random sampling and attempted to 
define the methods used appropriately (Newton et al. 2006). Certain studies that have used 
random sampling to minimize bias on deciding product quality include Amin and Snow 
(2005) and a study conducted in Laos (unpublished research cited in Newton et al., 2008). A 
review by Kelesidis et al. (2007) showed that in Nigeria counterfeit and under-standard types 
of antimalarials and antibiotics were found.  This does not necessarily mean that there are no 
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counterfeit forms of other drugs not mentioned here in Nigeria, as there is a likelihood that 
they may not have been sampled for tests.  
It is possible to counterfeit drugs of all clinical classes (Cockburn et al., 2005). Further 
demonstration by INTERPOL's current removals of drugs in Egypt and Asia, showed that 
counterfeits were in almost every branch of medicinal products (WHO 2010a). However, in 
developing countries such as Nigeria, the majority of counterfeited medicines such as 
antibiotics, antimalarials, and anti-infectives are life-saving (Bate et al. 2009). However, 
contrary to assumptions, counterfeiting are not the most costly drugs;  the economies make 
counterfeiting attractive even for the cheapest drugs. The findings of Ofonaike et al. (2007), 
in which drugs such as paracetamol and chloroquine were found to be of low quality, and  
according to Tipke et al. (2009),  chloroquine samples constituted a substantial proportion of 
poor quality. It could also have been that the errors found in these studies were due to poor 
quality control by legitimate suppliers. 
It was estimated that the second-largest distributor and producer of counterfeit medicines was 
Nigeria with about 23 percent of falsified drugs distributed all around the world after India. It 
was believed that 35 percent was from India and 13.3 percent from Pakistan. (Datta, 2003 
cited in Lybecker, 2004). The counterfeiting of medicines is said to be similar to the narcotics 
trade worldwide. In most cases, one country collects the raw materials, another formulates it 
into capsules and tablets, packaging is done in another country and then it ships through 
various countries until it gets to its final destination (Lybecker, 2007).  The Safe Medicines 
partnership is an example, as the Spanish police discovered that counterfeit medicines were 
being exported to Spain from Brazil, Thailand, and Mexico; and then sold in Portugal, France 
and Italy (Taylor and Craig, 2009). 
 
2.7 Sources of Poor Quality Medicine 
Three of the literature review studies obtained by (Onwujekwe et al. 2009), (Tipke et al. 
2009), and (Lon et al. 2006) examined sources of poor quality medicines. The study showed 
that drugs found in open places and streets were of low-quality because they are not well 
regulated. For example, patent medicine vendors accounted for 78 percent of suspect 
medicines in (Onwujekwe et al. 2009) and 90 percent of the medicines found to be under 
standard in (Tipke et al. 2009) were obtained from illicit outlets (markets, street vendors and 
28 
 
shops). A large proportion (100 out of 122) of samples from illegal or unlicensed outlets that 
did not pass quality testing were obtained  (Lon et al. 2006). 
In 2006, the National Agency for Food and Drug Administration and Control (NAFDAC) 
announced that the rate of counterfeit medicines had been decreased by as much as 70 
percent to about 16.7 percent from previous values (Taylor and Craig, 2009). Nevertheless, 
the rise in the rate of about 40 percent on the open drug market in Onitsha, popularly known 
as the head bridge market, is believed to have made this figure worse (Pharmaceutical 
Society of Nigeria (PSN) 2007; Okoye 2007 cited in Milissa McGinnis 2010). Other open 
drug markets in Nigeria that contributed to the high occurrence of non-standard and 
counterfeit drugs include the Ariaria market (alleged to have about 75 percent of drugs in 
stock as fake in 2002), the Sabon Gari market, Kano (a NAFDAC review showed that about 
90 percent of drugs are unregistered ) and the Idumota market, Lagos (PSN 2007).  With all 
this it is fit to ask if Nigeria should put more effort into curbing falsified medicines in areas 
that are supposed to be more prevalent. 
2.8  Activities And Interventions Of Nafdac In The Control Of Fake Drugs 
In April 2001, the “ new NAFDAC' activities was introduced and will be addressed in order 
to analyse how initiatives were being approved to control false drugs in Nigeria legal, 
structured market, as well as specific successes that took about a reduction in areas and 
problems that needs improvement.  All this will still be in comparism with other countries 
regulating agencies.  The offices of NAFDAC are located in 36 Nigerian states and  the six 
geopolitical zones with their national headquarters based in the federal capital territory of 
Abuja. 
2.8.1  NAFDAC Inspection Processes to Check Fake Drugs  
There are two inspection directorates involved in Nigeria. These are the Directorate of Ports 
Inspectorate (PID)  in charge of imported products, and the Directorate of Establishment 
Inspectorate (EID) in charge of locally produced products.  The  GMP(Good manufacturing 
processes) has a pricinple of  inspecting the finished product quality which is not just tested 
but built into the product. It is also perceived as a crucial component of pharmaceutical 
control. 
NAFDAC adopts the WHO recommendations for inspection visits for GMP and routine 
inspection but does not carry out regular inspections abroad mainly due to financial 
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constraints. Overseas industrial companies are checked once during the registration of the 
drug. These could result in manufacturers not completely adhering to the prescribed 
standards. Nevertheless, for the local products, unplanned daily visits to factories are carried 
out by inspectors.  Inspection rountines are now ongoing by The Ghana Food and Drug Board  
for both imported and local drug regulatory facilities, providing them with closer interaction 
and monitoring of drug manufacturers ' activities (Agyarko, 2006). 
Channels for the sale of drugs are hard to search in Nigeria. Due to unstable and unlicensed, 
trade owned by illitrates with profit-oriented interests. Other countries under review have 
identified ways to inspect the delivery of drugs. South Africa uses the local authorities in 
each region, while the UK and the Netherlands follow Good Distribution Practice (GDP), 
where the product distribution of the inspectors from the producer to the point of dispensation 
after registration. The Ghana Food and Drug Board is now undertaking regular daily 
inspections of both imported and local drug control facilities of the manufacturers of drugs 
(Agyarko 2006). 
Some NAFDAC Inspection Measures are 
•  All drug products that arrive the Nigeria’s port entry are required to supply pre-
shipment details.  
• All banks in Nigeria are to work in accordance with the information of NAFDAC that 
drug importers should receive clearance from the Agency first before they process the 
financial documents.  
• Issuance of guidelines for airlines that could lift importers ' drugs without the required 
authorization from the Agency.  
• Unregistered and importation of drug products is subject to seizure, consequence and 
fine until it is registered..  
• Post-marketing monitoring would be carried out according to WHO specifications. 
• Procedures for mopping up counterfeit drugs already in circulation are set.  
•  Once in three months in local factories in Nigeria an inspection is carried out at the 
time of product registration without prior notice. This is to ensure that current GMP 
are not deviated under the criteria wew drugs are licensed.  
• Weak GMP factories, their goods are not permitted into the country.  
•  Fake and expired drug items worth billions of naira that are seized by PID and EID 
officals  are eventually destroyed. 
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2.8.2  Drug Product  Registration as a Check for Fake Drugs  
Registration of products is a process where the system detects drug counterfeiting and 
contamination. The government uses this powerful means to control the safety and good 
quality of goods and  how products are produced and offered for sale in Nigeria.  In a 
developing country where fake medication is of high problem, a 5-year valid license is too 
long; Uganda DRA only gives a one-year license that will help to track drug products more 
closely. 
According to Nigerian drug law, drug sale, supply, and the price are one of the Agency's 
activities, but according to NAFDAC it is felt that regulation of products sold in companies is 
not among their jurisdiction and to that it is not monitored, because the  high tariffs were paid 
by the company to obtain their license. Once a drug product is registered, sometimes, until 
the company returns for renewal, one does not hear about what happens with the product. 
There is one monitoring unit in place for other countries under study.  Registration and 
review assistance from outside experts is unavailable. There's a lack of support from foreign 
experts who can come and teach the employees new ideas. 
Interventions by NAFDAC in the registration of drug product  
•  In order for a registration to be done by NAFDAC, the drug factory must be pre-
qualified by WHO or GMP  before the product is approved and can be shipped to 
Nigeria. 
• One of Nigeria's leading importers is India for drug products, NAFDAC named Indian 
analysts to assist in certifying every drug product before leaving India's shores to 
Nigeria.  
•  Registration number on products outer package is of high paramount by NAFDAC as 
they have demanded importers and their suppliers abroad that the product be 
registered before importation and brought to the shores of Nigeria. (NAFDAC 2007). 
• Assembling of all goods with "NAFDAC Green Page" and Registered with the 
Agency in the Gazette to inform the public about the items registered and what to 
purchase.  
• The  Director- General of NAFDAC, made a quick registration process of a maximum 
of two months to  help the agency solve delay problems and the companies obtain 
their license on time. Under the "new NAFDAC," three thousand six hundred and 
thirty (3,630) products were registered under one year, compared with five thousand, 
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seven hundred and thirty-five (5,735) products registered under the old "NAFDAC" 
within seven years. 
 2.8.3 Enforcement activities as a Check to Faking Drug 
 The “new NAFDAC” establishment has helped to catch wrong drug makers and to increase 
public trust in the Agency. Two key factors that have played a crucial role in the enforcement 
activities are the Surveillance and promptness, these two key factors has been useful as it  has 
given better interventions. Nonetheless, in Nigeria there are certain parties and compliance 
that cause conflicts of interest by NAFDAC. In the ports '  collection of bribes from drug 
dealers by customs may occur, while the judiciary often averts laws and criminal penalties 
against violators as well as the police. This impacts policy efforts in achieving acceptable 
outcomes. The UK MHRA maintains close cooperation with key investors whose impact can 
affect the investigation, identification and prosecution of violators.  
NAFDAC Enforcement Measures 
•  Victims of falsified medicines and health professionals reports tip-off the media and 
that way, fake drug dealers can be tracked and arrested.  
• Regular raid on drug hawkers that confiscate and destroy the product, especially when 
they are unable to provide adequate location address invoices that could help the 
enforcement team track drug fakers and distributors.  
• Warehouse leased by property owners who are aware of who uses it to store fake 
drugs, will be held responsible if it proves difficult to track fake drug dealers. It gave 
the police prompt details about drug-fakers. 
• Project to create a model market for drugs in the country's six geographical zones 
under pharmacist control and management. 
2.8.4 Program of Public Enlightenment as a Check to Faking of Drug 
NAFDAC is encouraged under its enabling law section 14 to use the tools it has in 
advertising and supporting its activities, including a public awareness campaign that is an 
effective strategy that can be used in consumer awareness and the fight against the 
counterfeiting of goods regulated. (Consumer health, NAFDAC 2007). The use of public 
awareness campaigns as a strategy involves dialogues, educates as well as persuasion through 
various means such as use of billboards, alert notices for consumers, jingles on television, 
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publications of the lists of all identified fake regulated products in the media, prints and 
electronic media, use of Workshops, Seminars and Stakeholder Advocacy. 
The U.K MHRA has a 24-hour customer hotline service which is not yet open to NAFDAC 
but consumer complaints are always accepted. Recently, the use of SMS text messages from 
mobile phones has been implemented by the Ghana Food and Drug Board (GFDB) to 
authenticate the drug quality a customer buys. M pedigree is what this technology is called, 
which tends to electronically track drugs from the original producers to the pharmacy shops 
where the drugs are being dispensed. It lets the drug buyer know the product's source. 
Because 90 percent of the population use mobile phones, this technology will be successful 
(Amankwah 2006) 
NAFDAC Public Enlightenment Program Interventions  
• An annual contests to help catch younger generations in  Nigerian high schools ' 
clarification program on fake drug knowledge, is done to learn what their perception 
is about the ill effects caused by fake drug products in society.  
• NAFDAC formation on  high school user clubs, because it is assumed that young 
people pass on knowledge to their friends and others, educating young people about 
the dangers of fake drugs.  
• Cooperation with other related participants such as NDLEA, the Nigerian Bar 
Association (NBA), the Nigerian Standard Organization (SON), the military, customs 
port authorities, etc. as contained in the enabling decree to liaise with relevant 
stakeholders both outside and within the country which may assist in the fight against 
counterfeit drugs.  
• Establishment of a National Pharmacovigilance Center (NPC) which promotes the 
rational and safe use of medicinal products.  
• Steady newspapers of the list of fake / counterfeit products identified in the quarterly 
newsletter and in the public newspapers of NAFDAC.  
• The Agency's advocacy visits to international regulatory authorities in China and 
India to assist with the issue of the importation of fake drugs. 
• Publication of a blueprint covering the period 2005-2010 as a guide to the Fake Drugs 
program.  
• The "NAFDAC Green List" will be launched as a list of all licensed products to 
inform the public about the quality of the approved products in circulation.  
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• Publish warning notes for items in circulation that have public awareness issues.  
• Organized seminars and workshops for SMEs, describing the NAFDAC guidelines 
and what is required of them. 
2.9 Review of Empirical Literature 
A study conducted by Chinwendu (2008) to understand the efforts made by NAFDAC in 
controlling fake drug circulation reviewed various works of NAFDAC to identify their 
strength and weaknesses in this regards, the major players in the business of fake drugs as 
well as factors influencing their (Fake drugs) widespread in Nigeria. Results from the study 
showed that the inability to give an adequate penalty to the open drug markets which are not 
licensed, monitored and not regulated which forms the major distribution market contribute 
to the proliferation of fake drugs without control; and this is due to the fact that the 
government does not help the situation by not giving adequate penal sanctions to the 
offenders as written in the drug laws. In conclusion, NAFDAC has not been able to achieve 
any reasonable success in fighting fake drugs in Nigeria due to inadequate support by the 
government, stakeholders, police, and the judiciary. 
Another study by (Orga 2017), which aimed to determine the impact of NAFDAC on the 
quality management of the Nigerian manufacturing sectors, surveyed 315 workers using a 
survey questionnaire. Results from the study revealed that NAFDAC used market 
surveillance and routine inspection to ensure that the standard specifications are being 
complied with. It also revealed that the manufacturing sectors in Nigeria adopt quality 
management practices to a high extent. It went further to recommend that ensuring processes 
that incorporate quality during production is better than attempting to incorporate quality by 
inspection after the production process. 
Anibeze (2007) conducted a descriptive study to ascertain the degree to which the NAFDAC 
programme has achieved success in influencing the choice of drug consumers in Nigeria 
using a structured questionnaire on 1,338 secondary school teachers from the five south-
eastern stated of Nigeria. Findings from the study showed that secondary school teachers 
were very much aware of the NAFDAC registered drugs; they also agreed that there were 
some indigenous drug companies blacklisted by NAFDAC. The respondents further admitted 
that seeing or being able to view the NAFDAC registration number on the products they want 
to buy, brand loyalty, and the price of drugs influenced their choice of drugs to buy. The 
study further ascertained that many problems are still being encountered in identifying drugs 
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registered by NAFDAC. The study came to the conclusion that the chive of the drug was 
influenced very much by the drug control campaigns done by NAFDAC. 
Wogu et al. (2019) also conducted a study to investigate the influence or role played by the 
Mobile Authentication Service (MAS) in eliminating fake drug consumption in South-east 
Nigeria. A cross-sectional survey of 1000 respondents from the five states of south-east 
Nigeria was made using a structured questionnaire. Results from the study revealed that there 
wasn’t a good level of awareness of the MAS scheme and that MAS made no impact on the 
distribution and consumption of counterfeit or fake drugs. It further revealed that the reason 
for the ineffectiveness of the MAS scheme was attributed to the inability of people to procure 
appropriate phone technology, a low level of awareness of MAS scheme media, and poor 
network services. It finally came to the conclusion that the MAS scheme of NAFDAC has not 
reduced or sopped the production, distribution, and consumption of fake drugs in South-east 
Nigeria.  
Finally, a cross-sectional survey by Oyetunde et al. (2019) which aimed to assess the 
acceptance of MAS by community pharmacists as well as examine what the MAS providers 
think are the challenges and success of developing MAS in Nigeria. They assessed 326 
community pharmacists and the MAS providers using both structured questionnaires and 
interviews respectively and found out that both perceived reliability and awareness played an 
important role in the behavioural intention of the use of MAS. It further explained that the 
challenges encountered with MAS, which were ‘no response and wrong response’ were 
mainly as a result of contextual challenges in the Nigerian setting including incessant power 
outages, Global System Mobile downtime, and the limited ability of the consumers to make 
use of the Short Message Service (SMS). These also contributed to the limited success of 
MAS in Nigeria. In the conclusion of the study, the level of acceptance of MAS by the 
community pharmacists is moderate; also, the major determining factors influencing 
behavioural intentions to use MAS were awareness and reliability; finally, the reason for the 
limited success of MAS development is due to its interactions with the local context, where it 







                                                          CHAPTER THREE 
METHODOLOGY 
3.1 Method 
Research Methodology is to be the major aspect of an investigation work as it helps the 
overall work in the proper direction to reach a suitable outcome (Harvey, Edrada-Ebel, and 
Quinn, 2015). When doing a study there are many approaches to choose from. Since different 
research studies involve various types of methods and choice behind which method 
considered to be the most suitable to use in this study has been carefully considered and 
argued for. The researcher’s core consideration is to choose the most appropriate 
methodology to carry out the work in an appropriate manner. The investigation into actual 
action is based on the evaluation of analysing the impact NAFDAC has on drug quality 
improvement in Nigeria.   
3.2 Research Philosophy 
The research philosophy forms the basis for how a researcher approaches theoretical and 
empirical knowledge (Saunders, Thornhill, & Lewis, 2012). This means that a research's 
theory is that which the researcher believes in his / her thesis. There are three key 
philosophies of research that explain how individuals perceive their surroundings and the 
whole world. There are interpretive philosophies, positivism, and realism (Bryman & Bell, 
2015).  
Interpretivism is a theory in which people and their actions are interpreted in a complex 
matter. This means that this approach seeks to explain how individuals in their social 
environment perceive and behave around a certain phenomenon (Bryman & Bell, 2015). The 
theory of interpretivism further suggests that individuals behave and perceive events 
differently from each other, implying that generalizations regarding their individual actions 
are difficult to draw (Saunders et al., 2012). 
In positivism, the learner is the individual who observes the research process. Positivism has 
been identified by Collins, H in accordance with the view of the empiricists that information 
comes from human expertise. It is a non-holistic, ontological world view that is composed of 
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distinct, measurable elements and events that behave in a measurable, normal, and decided 
manner. In this theory, the concepts are divided into three:  
 
 
i. The research's first goal is to describe and forecast  
ii. Empirical source of data, which can be measured by the human senses, is 
preferable. The theory must be tested while the work is ongoing. 
iii. Since the research is underway, the power of common sense may be curbed. 
 
Realism is just another form of philosophy. It should be known that the basic characteristic of 
realism is that anything humans would interpret as evidence should be regarded as reality. 
Realism emerged from an epistemology closely associated with positivism. The study of 
intelligence has both realism and positivism in common. These conventions make legitimate 
the research collection and analysis of data. For one to understand the true meaning of 
realism, the individual must know the two types of realism. The two styles are realism which 
is clear and critical. Selon Saunders (2012), is said to be simple realism 
According to the pragmatism theory, the learner cannot come to a conclusion without an in-
depth analysis of more than one view or idea. This means that the purpose of the philosophy 
of pragmatism is to figure out the realistic conclusion of the research subject. Although the 
purpose of this theory is to learn the various aspects of the selected subject, the work is not 
clearly obtained by accumulating a very large data source analysing, rather it gives credibility 
and validity importance. 
In this study, the aim is to investigate the major reason for fake drug consumption and the 
impact of NAFDAC in improving drug quality in Nigeria, the researcher chose positivism as 
the subject study philosophy, after suitable valuation and consideration. Making use of 
positivism will enable the learner to try not to have any influence on the research findings, 
instead, present oneself as the person who observes and is eager to use scientific and 





3.3 Research Approach 
The research approach is the research’s means of utilizing theories. The two basic research 
approaches that are commonly used in the research process are the deductive approach and 
the inductive approach (Bryan and Bell 2015). In the deductive approach, the researcher 
primarily develops a theory or hypothesis, then develops a design and different research 
strategies based on the theory or hypothesis; whereas, in the inductive approach, the 
researcher basically collects all possible data and makes an analytical study on the collected 
data. The researcher concludes a theory, which will explain the findings in detail based on the 
collected data.  
3.4 Research Design and Strategy 
A descriptive research design would be adopted by the study. A descriptive survey centers on 
describing the important facts about people, their opinion, motivations, and attitudes (Osuala 
2001). The researcher chose the descriptive research design because the main aim of the 
research is to describe the impact or role of NAFDAC in drug quality improvement or 
control. It will allow the researcher to get the opinions of the workers in pharmaceutical 
companies about their views on the role of NAFDAC in the control of drug quality in 
Nigeria.  
The research design determines the strategy chosen and as this study follows a descriptive 
research style, the most suitable research strategy to implement is a quantitative strategy. In 
addition, implementing a quantitative approach would allow the researcher to collect data 
from a good number of individuals as the researcher wished to study a large population. 
3.5 Research Choice 
Research choice pays attention to the correct method(s) to be used during the testing process. 
Mono, multiple, and mixed approaches are the various types of study choices. In the mono 
approach, the researcher chooses a single method and methodology for data collection and 
analysis; while the researcher can choose two or more methods of data collection and analysis 
in the multiple methods, e.g. the researcher can use both observation and questionnaire to 
collect data. The mixed approach includes the use of quantitative as well as qualitative 
techniques. The researcher in this review, however, preferred to apply the mono method to 




3.6 Time Horizon 
The two major categories of time horizon in a research context are the cross-sectional and 
longitudinal studies. Cross-sectional studies are studies performed at a specific point in time. 
Most academic studies are cross-sectional studies because they are performed within a given 
time frame and deadlines; whereas longitudinal studies appear more like the change or 
development, where the individual(s) or instances are meant to be studied by the researcher 
by observing closely and measuring for the time duration. However, this study researcher will 
utilize the cross-sectional study as the study is to be done within a specific period of time. 
3.7 Study Population and Sampling 
The targeted population is all the health professionals, NAFDAC officials, drug producers, 
and consumers in Enugu. The researcher will target mainly the doctors, Nurses, NAFDAC 
officials, Employees in pharmaceutical companies producing drugs who have had at least two 
years of working experience and the drug consumers. 
The sample size is said to be the number of items to be selected from a population to make a 
sample (Kothari 2004). The aim of sampling is to present the study population. This study 
will adopt a purposeful and random sampling technique. Purposeful sampling technique 
entails that the researcher will select the participants believed to be able to provide better and 
appropriate information; this means that the researcher will deliberately select the individual 
with the vital and reliable information required for the purpose of the study and they are the 
employed doctors and in UNTH and ESUTH teaching Hospitals; professionals working in 
Nemel Pharmaceutical and Juhel Nig. Ltd., Enugu; NAFDAC officials working in Federal 
Secretariat, Independence Layout, Enugu as well as the drug consumers residing in Enugu. 
The random sampling technique would be used when choosing the employed professionals in 
the various work offices who have had at least two years of working experience. Here, the 
respondents would be selected randomly and each individual will have an equal chance of 
being part of the sample. However, the researcher will use a sample size of about 37 






3.8 Data Collection Method and Instrument 
Data collection is a process of gathering relevant information concerning the subject matter 
of the study. There are different methods or techniques for data collection, including 
observation, interview, questionnaire, and focus group discussion methods. Selecting the 
appropriate data collection method id based on the research design and aims. For the purpose 
of this study, the questionnaire is the instrument that would be used to collect data. This is 
because it is can be easily used to obtain relevant information from many participants. The 
questionnaire will be semi-structured with open and close-ended questions as regards the 
subject matter of the study. 
3.9 Data Analysis 
The information obtained from the respondents with the questionnaire will be analysed using 
appropriate descriptive statistics of frequencies and percentages. The uniformity of the data 
collected would be assessed after which frequencies and percentages would be used to 
display the distribution of responses. The findings would be displayed in tables and charts 
and the results would be analysed using the Statistical Package for Social Sciences (SPSS). 
3.10 Ethical Consideration 
The research ethics includes the rules, principles, and traditions which are supposed to be 
followed to conduct the research.  The research ethics are followed at every step of the 
research paper. The research paper should include the consent of participants in the research 
work; it means no participants are involved by cheating or by force in the research work. 
Participants have every right to participate or not to participate in the research work.  It is 
important to treat the participants with the utmost dignity and dignity.  The privacy and 
confidentiality of the information should be assured to the participants. 
Research ethics involves the rules, values, and principles that should be followed in order to 
perform the research.  At each step of the research paper, the research ethics are followed. 
Some of the ethical considerations which would be observed by the researcher include: 
• The company management would be informed through a letter of introduction to the 
respondents  
• Oral consent would be sought officially as well by the researcher from the company’s 
human resource manager  
40 
 
• The researcher will ensure the privacy and confidentiality of the information given by 
the participants. 
• The researcher will as well avoid making use of statements and questions that can be 
deceptive while conducting the research. 
• The researcher will also ensure that the participants will only participate willingly and 
not coerced. 
• The researcher will also ensure that the participants will not be exposed to any form 




















                                                           CHAPTER FOUR 
DATA ANALYSIS AND FINDINGS 
The Data used for this research was obtained through responses from the questionnaires 
disseminated to a different group of people ranging from Professionals working in the 
pharmaceutical industry, Pharmacists, NAFDAC staff to the drug consumers, to ascertain 
their opinions concerning the drug situation and the role of NAFDAC in the improvement of 
drug quality in Nigeria. The questionnaires were disseminated via Linkedin social media 
platform to 37 individuals, including consumers of pharmaceutical products and people from 
various medical professional sectors in Nigeria. The result of the findings obtained from the 
participants would be analysed in this chapter.  
4.1 Demographic representations of the respondents 
4.1.1 The various groups/ segments of the respondent 
Table 4.1 The distribution of the respondent according to their respective segments 
Respondents Frequency % Frequency 
Professionals working in the Pharmaceutical industry 6 16.2% 
Pharmacists 4 10.8% 
Medical practitioners 4 10.8% 
NAFDAC Staff 5 13.5% 
Consumers 18 48.6% 

















Table 4.1 A funnel chart representing the distribution percentage of the respondents 
according to their respective segments 
 
Table 4.1 and Figure 4.1 show a distribution of the respondents according to the way they 
were grouped for this study. A total of 37 persons responded to the questionnaires. 18 
(48.6%) of them were consumers, 6 (16.2%) of them were professionals working in the 
Pharmaceutical industry, 4 (10.8%) of them were pharmacists while the remaining 4 (10.8%) 









4.1.2 The gender distribution of the respondents 
Table 4.2 The gender distribution of the respondents according to their different segments 
 Male Female Total 
Professionals working in the Pharmaceutical 
industry 
4(10.8%) 2(5.4%) 6(16.2%) 
Pharmacists 2(5.4%) 2(5.4%) 4(10.8%) 
Medical practitioners 2(5.4%) 2(5.4%) 4(10.8%) 
NAFDAC Staff 3(8.1%) 2(5.4%) 5(13.5%) 
Consumers 5(13.5%) 13(35.1%) 18(48.6%) 
Total 16(43.2%) 21(56.8%) 37 (100.0%) 
 
Fig 4.2 A clustered bar chart representing the gender distribution of the respondents 
according to their different segments  
Table 4.2 and Figure 4.2 show the gender distribution of the respondents according to their 
various groups. A total of 16 (43.2%) males and 21 (56.8%) females responded to the 
questionnaire. Out of the 16 males, 5 were consumers, 4 were professionals working in the 
pharmaceutical industry, 3 were NAFDAC staff, 2 were pharmacists while the remaining 2 
(5.4%) were medical practitioners. Out of the 21 females, 13 were consumers, 2 were 
professionals working in the pharmaceutical industries, another 2 were NAFDAC staff, and 2 
were pharmacists whereas the remaining 2 were medical practitioners. 
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4.1.3 The age group distribution of the respondents 
Table 4.3 The age group distribution of the respondents according to their different segments 
 
20-29yrs 30-39yrs 40-49yrs Total 
Professionals working in the Pharmaceutical industry 3(8.1%) 1(2.7%) 2(5.4%) 6(16.2%) 
Pharmacists 3(8.1%) 1(2.7%) 0(0%) 4(10.8%) 
Medical practitioners 3(8.1%) 1(2.7%) 0(0%) 4(10.8%) 
NAFDAC Staff 2(5.4%) 2(5.4%) 1(2.7%) 5(13.5%) 
Consumers 13(35.1%) 3(8.1%) 2(5.4%) 18(48.6%) 
Total 24(64.9%) 8(21.6%) 5(13.5%) 37 (100.0%) 
 
Fig 4.3 A clustered bar chart representing the age group distribution of the respondents according to 
their different segments  
Table 4.3 and Figure 4.3 above show the age distribution of the respondents according to 
their various groups. Out of all the (37) respondents, 24 (64.9%) of them were between ages 
20-29 years, 8 (21.6%) of them were between ages 30-39 years whereas only 5 (13.5%) of 
them were between ages 40-49 years. Out of the 24 respondents who were between ages 20-
29 years, 13 of them were consumers, 3 were professionals working in the pharmaceutical 
industry, 3 were pharmacists, and another 3 were medical practitioners while the remaining 2 
were NAFDAC staff. Out of the 8 respondents who were between ages 30-39 years, 3 were 
consumers, 2 were NAFDAC staff, 1 was a professional working in the pharmaceutical 
industry, and another 1 was a pharmacist, whereas the remaining 1 was a medical 
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practitioner. Out of the 5 respondents who were between ages 40-49 years, 2 were 
consumers, another 2 were professionals working in the pharmaceutical industry, and the 
remaining 1 person was a NAFDAC staff while none was a pharmacist nor a medical 
practitioner.  
4.1.4 The highest educational qualification attained by the respondents 









Professionals working in the 
Pharmaceutical industry 0(0%) 4(10.8%) 2(5.4%) 6(16.2%) 
Pharmacists 0(0%) 3(8.1%) 1(2.7%) 4(10.8%) 
Medical practitioners 0(0%) 4(10.8%) 0(0%) 4(10.8%) 
NAFDAC Staff 1(2.7%) 3(8.1%) 1(2.7%) 5(13.5%) 
Consumers 2(5.4%) 7(18.9%) 9(24.3%) 18(48.6%) 
Total 3(8.1%) 21(56.8%) 13(35.1%) 37 (100.0%) 
 
 
Fig 4.4 A bar chart displaying the highest educational qualification attained by  the 




Table 4.4 and Figure 4.4 displayed the distribution of the highest educational qualification 
attained by the respondents according to their various segments. Out of all the (37) 
respondents, 3 (8.1%) of them had Certificate/Diploma as their highest attained educational 
qualification, 21 (156.8%) had bachelor’s degree/advanced diploma, while the remaining 13 
(35.1%) of them had master’s degree as their highest attained educational qualification. Of 
the 3 respondents who had certificate/diploma, 2 of them were consumers, 1 of them was a 
NAFDAC staff whereas none was a Pharmacist, Medical practitioner, or a professional 
working in the pharmaceutical industry. Also, out of the 21 respondents who had bachelor’s 
degree/advanced diploma, 7(18.9%) were consumers, 4 were professionals working in the 
pharmaceutical industry, another 4 were medical practitioners, 3 were pharmacists, while the 
remaining 3 were NAFDAC staff. Finally, out of the 13 respondents who had a Master’s 
degree, 9 were consumers, 2 were professionals working in the pharmaceutical industry, 1 
was a pharmacist, and another 1 person was a NAFDAC staff while none was a medical 
practitioner. 
 
4.1.5 The distribution of the work experience of the professional respondents 
Table 4.5 The distribution of the work experience of the professional respondents according 
to their different segments 
  Less than 2Years 2- 5 years more than 5 years 
Professionals working in 
the Pharmaceutical 
industry 1(5.3%) 3(15.8%) 2(10.5%) 
Pharmacists 0(0%) 1(5.3%) 3(15.8%) 
Medical practitioners 1(5.3%) 2(10.5%) 1(5.3%) 
NAFDAC Staff 1(5.3%) 2(10.5%) 2(10.5%) 







Fig 4.5 A bar chart representing the work experience of the professional respondents 
according to their different segments 
 
Table 4.5 and Figure 4.5 above displayed the distribution of the work experience of the 
professionals according to their various segments. Out of the 19 professionals who responded 
to this question, only 3 (15.8%) of them have had 2 years of working experience, 8 (42.1%) 
of them have had 2-5 years of working experience while the remaining 8 942.2%) of them 
have had more than 5 years of working experience. The 3 of the professionals who have had 
less than two years of working experience including 1 professional working in the 
pharmaceutical industry, 1 medical practitioner and 1 NAFDAC staff. Also, out of the 8 
respondents who have had 2-5 years of working experience, 3 of them are professionals 
working in the pharmaceutical industry, 1 of them is a pharmacist, and 2 of them are medical 
practitioners whereas the remaining 2 of them were NAFDAC staff. Lastly, out of the 8 
respondents who have had more than 5 years of working experience, 2 of them are 
professionals working in the pharmaceutical industry, 3 of them are pharmacists, and 1 of 







4.2 Analysis of Objective One: To understand the perception of various group of 
individuals in Nigeria about the drugs produced in the country 
4.2.1 Do you agree or disagree with the statement that medicinal 
products in Nigeria are of low quality? 
 
Table 4.6 The perception of participants on their agreement or disagreement that medicinal 




Agree Neutral Disagree 
Strongly 
Disagree 
Professionals working in 
the Pharmaceutical 
industry 
1(16.7%) 2(33.3%) 2(33.3%) 1(16.7%) 0(0%) 
Pharmacists 0(0%) 2(50.0%) 1(25.0%) 1(25.0%) 0(0%) 
Medical practitioners 0(0%) 2(50.0%) 0(0%) 2(50.0%) 0(0%) 
NAFDAC Staff 1(20.0%) 2(40.0%) 2(40.0%) 0(0%) 0(0%) 
Consumers 1(5.6%) 6(33.3%) 5(27.8%) 2(11.1%) 4(22.2%) 
Total 3(8.1%) 14(37.8%) 10(27.0%) 6 (16.2%) 4(10.8%) 
 
 
Table 4.6 shows a distribution of the extent to which the various participants believe with the 
statement that Nigerian medical products are of low quality. Out of all the (37) respondents, 
17(45.9%) of the respondents were in agreement with the statement, 10 (27.0%) of them were 
neutral, while the remaining 10 (27.0%) were in disagreement with the statement. The 17 
respondents in agreement with the statement were: 3 (50.0%) of the professionals working in 
the pharmaceutical industry, 2 (50%)) of the pharmacists, 2 (50%) of the medical 
practitioners, 3 (60.0%) of the NAFDAC staff, and 7 (38.9%) of the consumers. Also, the 10 
respondents who were neutral to the statement include 2 (33.3%) of the professionals 
working in the pharmaceutical industry, 1 (25%) of the pharmacists, none (0%) of the 
medical practitioners, 2 (40%) of the NAFDAC staff, and 5 (27%) of the consumers. Finally, 
the remaining 10 respondents who were in disagreement with the statement include 1 (16.7%) 
of the professionals working in the pharmaceutical industry, 1 (25.0%) of the pharmacists, 2 




4.3 Analysis of Objective Two:  
To find out the preferred type of drugs (locally produced or foreign) bought by 
consumers or prescribed by medical practitioners in Nigeria. 
4.3.1 What type of drug would you prefer to recommend to your patients/customers? 
 
Table 4.7 The distribution of the preferences of medical products made in Nigeria/abroad. 









Professionals working in 
the Pharmaceutical 
industry 1(16.7%) 3(50.0%) 2(33.3%) 6(42.9%) 
Pharmacists 1(25.0%) 1(25.0%) 2(50.0%) 4(28.6%) 
Medical practitioners 0(0%) 2(50.0%) 2(50.0%) 4(28.6%) 
Total 2(14.3%) 6(42.9%) 6(42.9%) 14(100%) 
 
Table 4.7 displays  the distribution of the preferences of medicinal products that are made in 
Nigeria or abroad. The table shows that out of the 14 professionals who responded to the 
question, 6 (42.9%) of them preferred to recommend drugs produced abroad to customers, 6 
(42.9%) of them had no preference, while only 2 (14.3%) of them prefer to recommend  
drugs produced in Nigeria to customers. The 6 respondents who preferred to recommend 
drugs produced in abroad were 3 (50.0%) of the professionals working in the pharmaceutical 
industry, 1 (25.0%) of the pharmacists, and 2 (50%) of the medical practitioners prescribed 
drugs produced in abroad to consumers. Also, the 6 respondents who had no preference for 
drug recommendation include 2 (33.3%) of the professionals working in the pharmaceutical 
industry, 2 (50.0%) of the pharmacists and another 2 (50.0%) of the medical practitioners had 
no preferences to prescribe drugs to consumers. Finally, the remaining 2 respondents who 
preferred to recommend drugs produced in Nigeria were: 1 (16.7%) of the professionals 
working in the pharmaceutical industry and the remaining 1 (25.0%) of the pharmacists; none 






4.3.2 What type of drugs do you prefer to buy? 
 
Table 4.8 A display of consumers’ preferences to their choice of drugs 
What type of drugs do you prefer 
to buy? 
Frequency % Frequency 
Drugs produced abroad 14 77.8 
Drugs produced in Nigeria 4 22.2 





Fig 4.6 A bar chart displaying the consumers’ preferences to their choice of drugs 
 
Table 4.8 and Figure 4.6 above displayed the consumers’ responses to their preference for 
drugs to purchase with respect to where they were produced. Out of all the consumers, 14 
(77.8%) of them chose ‘drugs produced abroad, indicating that they prefer purchasing drugs 
which were not produced in Nigeria, while the remaining 4 (22.2%) of them chose ‘drugs 




4.4 Analysis of Objective Three:  
To identify the major contributing factors to the production and distribution of low-
quality drugs in Nigeria 
Table 4.9 A distribution of respondents’ perception about major factors that can influence or 








in the drug 
business 
Inadequate laws or 
poor enforcement of 

















16.7 0.0 16.7 33.3 0.0 
Agree 50.0 16.7 50.0 50.0 0.0 
Neutral 33.3 16.7 33.3 16.7 33.3 
Disagree 0.0 50.0 0.0 0.0 50.0 
Strongly 
Disagree 




0.0 25.0 25.0 50.0 0.0 
Agree 75.0 75.0 75.0 50.0 0.0 
Neutral 25.0 0.0 0.0 0.0 50.0 
Disagree 0.0 0.0 0.0 0.0 25.0 
Strongly 
Disagree 





25.0 25.0 50.0 25.0 0.0 
Agree 25.0 25.0 25.0 25.0 50.0 
Neutral 0.0 25.0 0.0 0.0 0.0 
Disagree 50.0 0.0 25.0 25.0 50.0 
Strongly 
Disagree 





0.0 0.0 0.0 0.0 0.0 
Agree 20.0 0.0 0.0 0.0 0.0 
Neutral 40.0 0.0 20.0 60.0 40.0 
Disagree 40.0 40.0 60.0 40.0 40.0 
Strongly 
Disagree 
0.0 60.0 20.0 0.0 20.0 




Agree 38.9 27.8 27.8 27.8 11.1 
Neutral 22.2 16.7 16.7 27.8 22.2 
Disagree 11.1 5.6 5.6 5.6 27.8 
Strongly 
Disagree 
11.1 27.8 16.7 11.1 27.8 
 
 
Fig 4.7 A clusterd bar of the distribution of respondents’ perception about major factors that 
can influence or impact on the quality of medicinal products in Nigeria 
Table 4.9 and Fig 4.7 above shows a distribution of the respondents’ level of agreement to the 
major contributing factors to the production and distribution of low-quality drugs in Nigeria. 
With respect to the statement that the high cost of good quality drugs is a major contributing 
factor, 66.7% of the professionals working in the pharmaceutical industry were in agreement 
that it is a major contributing factor, 33.3% of them were neutral to the statement while none 
(0.0%) of them were in disagreement to the statement; 75% of the pharmacists were in 
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agreement to the statement, the remaining 25% of them were in disagreement while non 
(0.0%) of them disagreed to the statement; 50% of the medical practitioners agreed to the 
statement, none were neutral, while the remaining 50% of them disagreed to the statement; 
only 20% of the NAFDAC staff were in agreement with the statement, 40% were neutral 
whereas the remaining 40% disagreed to that; of all the consumers, 55.6% of them were in 
agreement, 22.2% of them were neutral, while the remaining 22.2% of them were in 
disagreement with the statement that high cost of good quality drugs is a major contributing 
factor to the production and distribution of low quality drugs in Nigeria.  
With respect to the statement that Non-health professionals in the drug business are a 
contributing factor to the production and distribution of low-quality drugs in Nigeria, 16.7% 
of the professionals working in the pharmaceutical industry agreed to the statement, another 
16.7% of them were neutral, while the remaining 66.7% of them were in disagreement with 
the statement; 100% of the pharmacists agreed to this statement, while none of them were 
neutral or in disagreement with it; 50% of the medical practitioners were in agreement with 
the statement, 25% of them were neutral while the remaining 25% of them were in 
disagreement with the statement; out of all the NAFDAC staff, none of them were in 
agreement or neutral to the statement while 100% of them disagreed to the statement; 50% of 
the consumers agreed to this statement, 16.7% of them were neutral while the remaining 
33.4% of them were in disagreement with the statement.  
With respect to the statement that the inadequate laws or poor enforcement of the existing 
drug quality control regulations is the major contributing factor to the production and 
distribution of low quality drugs in Nigeria, 66.7% of the professionals working in the 
pharmaceutical industry agreed to the statement, the remaining 33.3% of them were neutral to 
it whereas none of them were in disagreement to the statement; also, of all the pharmacists 
who responded to this statement, 100% of them agreed to it while none of them were neutral 
or in disagreement with the statement; 75% of the medical practitioner were in agreement 
with this statement, none of them were neutral while the remaining 25% of them disagreed 
with it; out of all the NAFDAC staff, none of them agreed with the statement, 20% were 
neutral while the remaining 80% were in disagreement with the statement; finally, 55,6% of 
the consumers agreed to the statement, 27.8% of them were neutral while the remaining 
16.7% of them disagreed to it.  
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With respect to the statement that inadequate drug distribution monitoring system is a major 
contributing factor to the production and distribution of low-quality drugs in Nigeria, 83.3% 
of the professionals working in the pharmaceutical industry agreed to this statement, the 
remaining 16.7% of them were neutral to it while none of them disagreed to it; also, out of all 
the pharmacists, 100% of them were in agreement with the statement, while none was neutral 
or disagreed with it; 50% of the medical practitioner agreed to the statement, none was 
neutral while the remaining 50% were in disagreement with it; out of all the NAFDAC staff, 
none of them was in agreement with the statement, 60% of them were neutral, whereas the 
remaining 40% of them were in disagreement with it; lastly, 55.6% of the consumers were in 
agreement with this statement, another 27.8% of them were neutral while the remaining 
16.7% of them were in disagreement with the statement.  
Finally, with respect to the statement that demand exceeding supply is a major contributing 
factor to the production and distribution of low quality drugs in Nigeria, none of the 
professionals working in the pharmaceutical industry was in agreement with this statement, 
33.3% of them were neutral while the remaining 56.7% of them were in disagreement with it; 
also, none of the pharmacists was in agreement with this statement, 50% of them were neutral 
while the remaining 50% of them were in disagreement with the statement; more so, 50% of 
the medical practitioners were in agreement with this statement, none of them was neutral 
while the remaining 50% were in disagreement with it; again, none of the NAFDAC staff was 
in agreement with this statement, 40% of them were neutral while the remaining 60% of them 
were in disagreement with it; finally, 22.2% of the consumers were in agreement with the 
statement, another 22.2% of them were neutral whereas the remaining 55.6% of them were in 
disagreement with the statement.  
4.5 Analysis of Objective Four:  
To identify and assess the control measures used by NAFDAC in ensuring the 
production of good quality drugs and how compliant all individuals are to them 
4.5.1 What measures have been taken by NAFDAC to control the production and 
distribution of low-quality medicinal products in Nigeria? 
The above question was directed to the NAFDAC staff. Some of the respondents who 
answered this question indicated that “NAFDAC agency has set up enforcement officers for 
control and constant routine inspection by designated inspectors”. Another response given by 
them was the “provision of mobile authentication of original drugs” and thirdly, “Putting in 
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place disciplinary measures in law against fake drug production and unlicensed drug 
distribution”. 
4.5.2 How often does NAFDAC inspect your drug production process? 
Table 4.10 A response showing the perception of pharmaceutical professionals’ to the 
inspection of NAFDAC on their companies’ drug production process 
How often does NAFDAC 
inspect your drug production 
process? 
Frequency % Frequency 
Very Often 1 16.7 
Often 3 50.0 
No idea 1 16.7 
Seldom 1 16.7 
very seldom 0 0 
 
 
Fig 4.8 A Funnel chart showing the distribution of  responses given by professionals working 
in the pharmaceutical industry on NAFDAC’s inspection on their companies drug production 
process 
Table 4.10 and Figure 4.8 show a distribution of the responses given by the professionals 
working in the pharmaceutical industry about how often the drug production process is being 
inspected by NAFDAC. It shows that 1 (16.7%) of them answered ‘very often’, 3 (50%) of 
them answered ‘often’ showing that NAFDAC often inspects their drug production process; 
however, 1( (16.7%) of them answered ‘no idea’, indicating he/she cannot tell how often this 
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was done, the remaining 1 (16.7%) of them answered ‘seldom’ while none answered ‘very 
seldom’; this shows that only one person indicated that NAFDAC does not often inspect their 
drug production process. 
4.6 Analysis of Objective Five: To determine the degree to which the objective of drug 
quality improvement has been achieved in Nigeria. 
4.6.1 Do you think NAFDAC is improving the quality control of the production and 
distribution of medicinal products in Nigeria? 
 
Table 4.11  The Perception of  Pharmacists on the improvement of the quality control of 
production and distribution of medicinal products in Nigeria  
Do you think NAFDAC is improving 
the quality control of the production 
and distribution of medicinal products 
in Nigeria? 
Frequency % Frequency 
Yes 3 75 
No 1 25 
Total 4 100 
 
 
Fig 4.9 A bar chart displaying the responses of the pharmacists  on the improvement of 
NAFDAC  quality control on production and distribution of medicinal products in Nigeria  
Table 4.11 and Figure 4.9 above revealed the perceptions of the pharmacists on the 
improvement of drug production and distribution quality control by NAFDAC. With respect 
to this, 3 (75.0%) of the respondents answered ‘yes’ indicating that they believe that 
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NAFDAC is improving the quality control of the production and distribution of medicinal 
products in Nigeria, whereas only 1 (25.0%) of them answered ‘no’ indicating they don’t 
believe the statement.  
4.6.2 Do you think the degree of fake drug distribution in Nigeria has reduced within 
the last ten years? 
Table 4.12  The response of  the medical professionals  perception on the degree of fake drug 
distribution reduction in Nigeria within the last ten years 
 
Do you think the degree of fake drug 
distribution in Nigeria has reduced within 
the last ten years?  
Frequency % Frequency 
Yes 2 50.0 
No 2 50.0 
Total 4 100.0 
 
 
Fig 4.10 A bar chart displaying the responses of the medical professionals on their perception 
of the degree of fake drug distribution reduction in Nigeria within the last ten years 
Table 4.12 and figure 4.10 above displayed the responses of the medical professionals 
perception on the degree of fake drug distribution in Nigeria has reduced within the last 10 
years. 50% of them answered ‘yes’ to the question, indicating that they believe the degree of 
fake drug distribution in Nigeria has reduced within the last 10 years, while the other 50% of 
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them answered ‘no’ to the question indicating they don’t believe the degree of fake drug 
distribution in Nigeria has reduced within the last 10 years. 
 
4.6.3 Can you identify if your purchased drugs are fake or authentic? 
 
Table 4.13 A display of consumers responses ability to identify fake drugs 
Can you identify if your 





Yes 5 27.8 
No 13 72.2 
Total 18 100.0 
 
 
Fig 4.11 A bar chart showing the responses of consumers’ ability to identify fake drugs 
 
Table 4.13 and figure 4.11 above showed the consumers’ responses about their ability to 
identify fake or authentic drugs. From the table and figure above, 5 (27.8%) of them 
answered ‘yes’ to the question, indicating they are able to identify if they purchased fake or 
authentic drugs; while 13 (72%) of them answered ‘no’ to the question, indicating they are 
not able to identify if they have purchased fake or authentic drugs. 
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                                                        RESULTS 
This chapter attempts to discuss the major findings from the analysis above in relation to the 
objectives of this research, after which the findings from this study would be compared with 
that of other related studies on drug quality.  
The first objective sought to outline the perception of various groups of people with different 
professional backgrounds that are involved in the production and distribution of medicinal 
products in Nigeria, as well as random consumers: 
o Group A: professionals working in the pharmaceutical industry; Pharmacists; 
Medical professionals. 
o Group B: NAFDAC – Organization that is responsible to control of Quality of 
Medicinal products in Nigeria. 
o Group C: Consumers in Nigeria. 
Findings from the analysis with respect to this objective revealed that most of the participants 
agreed that medical products produced in Nigeria are of low quality. Also, it was noted that a 
greater percentage of NAFDAC staff, pharmacists, and medical practitioners agree with the 
statement in comparison to others. This finding is similar to that of Ebenezer (2015), who 
conducted a qualitative study and reported the perceived existence of poor quality medicine 
in Nigeria with perceived increased level of poor quality medicine in Nigeria reported by 
mainly the community pharmacists and patent medicine vendor groups in comparison with 
other groups. According to him, the reason for this was due to their personal experiences as 
some of them have encountered various illegal drug hawkers on the streets and public 
transports, some have encountered patients who bought prescribed drugs from nearby 
vendors which failed to work and when checked, they noticed it had no NAFDAC 
registration number, etc (Ebenezer, 2015).  
Secondly, the second objective sought to find out the preferred type of drugs (locally 
produced or foreign) bought by consumers or prescribed by medical practitioners in Nigeria. 
The researcher asked two questions, one to the professionals and the other to the consumers 
in order to ascertain this. Findings from the result revealed that majority of the professionals 
including the pharmacists, medical practitioners and the professionals working in the 
pharmaceutical industries indicated they prefer to recommend drugs produced abroad to that 
produced in Nigeria for their patients/customers; it also revealed that customers prefer to buy 
foreign drugs to that produced in Nigeria. This implies that foreign-made drugs are more 
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valued by Nigerians, which may probably be because many of them must have encountered a 
series of fake drug dealers in one way or the other. Many Nigerians do not trust drugs 
produced in their home country. This finding is in consensus with the findings from the first 
objective as the majority of the respondents has had the perception that drugs produced in 
Nigeria are of low quality, they will definitely prefer recommending/buying foreign drugs 
because the consequences of consuming fake drug products are most often costlier than 
purchasing original drugs.  
Furthermore, the third objective sought to identify the major contributing factors to the 
production and distribution of low-quality drugs in Nigeria. Five factors were listed and each 
of the respondents was asked to specify their level of agreement or disagreement that each of 
the listed factors contributes majorly to the production and distribution of low-quality drugs 
in Nigeria. The factors include High cost of good quality drugs, non-health professionals in 
the drug business, inadequate laws or poor enforcement of the existing drug quality control 
regulations, inadequate drug distribution monitoring system, and demand exceeding supply. 
Findings from the results as regards this objective are: First, majority of the respondents 
agreed that high cost of good quality drugs is a major contributing factor to the production 
and distribution of good quality drugs; also, the pharmacists, professionals working in the 
pharmaceutical industry and the consumers had a greater percentage of agreement in 
comparison with the other groups. This finding is agreeable because these group of people is 
the ones who are directly affected by the cost of the drugs as pharmaceutical companies 
would spend more to produce the drug products, sell at a higher price to the pharmacists who 
will now dispense/sell to the consumers at the same high cost. If the cost of producing high-
quality drugs are high, it would encourage the fake drug dealers to start imitating and 
producing fake drugs so as to sell faster; and as a good number of Nigerians live below 
poverty level, many drug users may not be buoyant enough to purchase good quality drugs 
and, therefore, would be forced to buy the affordable ones which are of lower quality. 
More so, with respect to the second listed factor which is ‘non-health professionals in drug 
business’, overall, the majority of the respondents were in agreement with this. A greater 
percentage of the pharmacists, medical practitioners, and the consumers, when compared to 
the other groups, agreed with this statement. In Nigeria, the least required qualification for an 
individual to be licenced as a drug dealer in Nigeria is the first school leaving certificate. As a 
result of this, most of the non-health professionals in drug businesses may not be able to 
differentiate fake from original drugs as most of them may have not attended a higher 
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institution to study all about drugs (Erhun et al., 2001). This finding is in consensus with the 
findings of Chinwendu (2008), and Erhun et al. (2001), in whose study, the majority of the 
respondents indicated that non-health professionals in the drug business are a major 
contributing factor to the production and distribution of low-quality drugs in Nigeria. This 
finding is also similar to that of Ebenezer (2015), who noted that Ignorance and lack of 
awareness is one of the major contributing factors. 
Again, most of the respondents also agreed that inadequate laws or poor enforcement of the 
existing drug quality control regulations are a major contributing factor to the production and 
distribution of low-quality drugs in Nigeria. If there are no appropriate laws governing drug 
production and distribution in the country, and, if the defaulters of these drug laws are not 
punished as appropriate, people tend to be more encouraged to produce and distribute fake 
drugs. This finding is in agreement with the finding of Chinwendu (2008), in which all the 
participants who participated in her study agreed that inadequate laws or poor enforcement of 
the existing drug quality control regulations are a major contributor to the production and 
distribution of low-quality drugs in Nigeria. However, the result revealed that none of the 
NAFDAC staff was in agreement with this statement. This may be because they believe that 
NAFDAC always does its best to enforce the drug law and punish defaulters as appropriate.  
Ebenezer (2015) revealed a similar finding, indicating that only a few of the respondents 
chose this factor as a major contributing factor to the production and distribution of low-
quality drugs in Nigeria. 
Lastly, a good number of the participants agreed that an inadequate drug distribution 
monitoring system is a major contributing factor to the production and distribution of low-
quality drugs in Nigeria. This finding is also in agreement with that of Olike (2008) who also 
revealed that Demand exceeding supply is not a major contributing factor to the production 
and distribution of fake or low-quality drugs in Nigeria. 
More so, the fourth objective sought to identify and assess the control measures used by 
NAFDAC in ensuring the production of good quality drugs. The researcher used two 
questions to address this objective. The first question was directed to the NAFDAC staff to 
ascertain their views about the control measures used by NAFDAC in ensuring production 
and distribution of good quality drugs, while the second question was directed to the 
professionals working in the pharmaceutical industry in order to ascertain how often 
NAFDAC inspect the drug production process in their company. Findings from the result 
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showed that NAFDAC uses some control measures like setting up enforcement officers for 
control and routine inspection, provision of mobile authentication of original drugs to help 
consumers identify which drugs are fake or original, and also putting in place disciplinary 
measures against fake drug production and unlicensed drug distribution in the law. Also, 
findings revealed that NAFDAC often inspects the drug production process in pharmaceutical 
companies. According to the findings from a study conducted by Orga (2017) on the impact 
of NAFDAC on quality management of Nigerian manufacturing sector, routine inspection of 
the pharmaceutical company was one of the measures used by NAFDAC to ensure 
compliance with standard specifications, which is in agreement with the finding from this 
study.  
Finally, the Fifth objective sought to determine the degree to which the objective of drug 
quality improvement has been achieved in Nigeria. The researcher used three questions to 
address this objective. The first question sought to find out if NAFDAC activity is improving 
the quality control of the production and distribution of drugs in Nigeria. The second question 
sought to find out from the participants their perception about whether fake drug production 
and distribution has reduced in Nigeria within the last 10 years, while the last question sought 
to know if the consumers were able to identify if their purchased drugs were fake or 
authentic. Findings from the result showed that most of the participants believe that 
NAFDAC activity is improving the quality control of the production and distribution of 
medicinal products in Nigeria. Also, there is an equal percentage of agreement and 
disagreement as to whether the fake drug distribution and production have reduced. 
Additionally, most of the consumers indicated, from the last question, that they cannot 
ascertain whether the drugs they purchased are fake and original. Findings from the fifth 
objective imply that NAFDAC has put up many measures and strategies to curtail production 
and distribution of low-quality drugs but some members of the public are not very familiar 
with how to utilize some of them like the mobile authentication service. A finding from a 
similar study conducted by Wogu et al. (2019) on the influence of NAFDAC mobile drugs 
authentication service on the use of fake drugs among Consumers in Southeast Nigeria is also 
in agreement with the finding from this objective, as he noted there was a low level of 
awareness of the Mobile authentication service by the public This may likely be one of the 
contributing factors to the distribution and even consumption of low-quality drugs because 
since consumers are not aware of this, they would find it difficult to differentiate the fake 




                                                             CHAPTER FIVE 
                                 CONCLUSION AND RECOMMENDATION 
This is the conclusion and recommendation chapter, of which there is a more elaborate 
discussion on what NAFDAC has done so far and what will be recommended they should do 
going forward to control the spread of counterfeit medicinal products in Nigeria. 
Findings from the study have revealed how individuals from different professional 
backgrounds who are involved in the production and distribution of medical products in 
Nigeria, as well as the random consumers, perceive medical products produced in Nigeria, 
the factors influencing the production and distribution of low-quality drugs, the role of 
NAFDAC in improving drug quality, and the current situation of Nigeria with respect to drug 
quality. The study had five objectives that summarily boiled down to understanding the role 
of NAFDAC in improving drug quality in Nigeria. 
From the first objective, it was concluded that the respondents, mainly the NAFDAC staff 
and the medical practitioners believe that drugs produced in Nigeria are of low quality. Also, 
findings from the second objective pointed out that the professionals, as well as the 
consumers, prefer to recommend and /or purchase foreign-made drugs to the locally 
(Nigerian) made ones.  
Furthermore, it was deduced from the third objective that the high cost of good quality drugs, 
inadequate laws, or poor enforcement of the existing drug quality control regulations and the 
inadequate drug distribution monitoring system were the three major factors influencing the 
production and distribution of low-quality drugs in Nigeria. More so, setting up enforcement 
officers for control and routine inspection, provision of mobile authentication of original 
drugs to help consumers identify which drugs are fake or original are some of the control 
measures put up by NAFDAC to combat fake drug production and distribution in Nigeria; 
Finally, findings from the last objective revealed that there was an equal percentage of 
agreement and disagreement as to whether the problem of fake drug production and 
distribution has reduced in Nigeria in the last 10 years; it also revealed that majority of the 




In conclusion, NAFDAC is doing its best to combat the problematic drug situation in Nigeria, 
but more efforts and awareness are still needed to make them more effective as to help to stop 
the spread of fake drugs and also to protect various group of individuals. Also, from my 
research in conclusion it shows that most individuals still need an awareness to the 
distribution and purchasing of counterfeit medicinal products and the control measures put in 
place by NAFDAC will need to be improved. 
The researcher, therefore, recommends that the cost of producing drugs in Nigeria should be 
subsidised by the government as these would make good quality drugs affordable for the 
consumers so that they would have no reason to purchase drugs of lower quality. More 
stringent drug laws/policies and punishments for defaulters should also be enforced to 
discourage fake drug production and distribution in the country. Again, the researcher further 
recommends that NAFDAC should increase the awareness for the use of the mobile 
authentication service so as to help the consumers identify the fake drug products from the 
original ones. In these ways, the problem of the production and distribution of fake medical 
products would be reduced in Nigeria. The awareness of counterfeit medicinal products 
should be well known by individuals as NAFDAC work on all there control measures that 
have been put in place by improving on it and also they should work on the officials put in 
place for distribution of medicinal products to check all medicinal products are well 
numbered and labelled appropriately. 
Also, will recommend that in future NAFDAC uses some of the guidelines from ICH, that 
way it will help them more on their guidelines and help improve their work in the control of 
low-quality medicinal products in Nigeria. The researcher would recommend that there be 
some form of free  anti-malaria medicinal products for everyone as malaria is one of the high 
level of sickness and deaths in Nigeria. Futhermore, a recommendation would be that 
medicinal products in Nigeria should be authenticated so that individuals can appreciate 
medicinal products in Nigeria and not seen as low-quality drugs as long as they put all control 
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  This is a research being conducted by a student of Griffith College Dublin.   
Your participation in this research study is voluntary. You may choose not to participate. If you 
decide to participate in this research survey, you may withdraw at any time. If you decide not to 
participate in this study or if you withdraw from participating at any time, you will not be 
penalized. 
 
The procedure involves filling an online survey that will take approximately 4-7 minutes. Your 
responses will be confidential and we do not collect identifying information such as your name 
or email address. To help protect your confidentiality, the surveys will not contain information 






Tick  against the appropriate answer 
 
1. Gender               __________           Male                Female 
 
 
2. Please indicate your age    ___         <20            18-29yrs  
 
            30-39yrs                 50-59yrs                  60+yrs 
 
 
3. What is your  level of education?     
 
 Certificate/Diploma  
 
Bachelor’s degree/Advanced diploma  
       
Master’s degree  
 




















Please tick the appropriate box: 
 
1. What is your opinion about the quality of medicinal products in 
Nigeria? 
 




a. Do you agree or disagree wth the statement that medicinal products in Nigeria are 
low quality? 
Strongly Disagree 
 Disagree  
            Neutral  
              Agree  
            Strongly Agree 
 
b. Do you agree or disagree wth the statement that pharmaceutical companies based 
in Nigeria are producing and distributing low quality medicine? 
 
Strongly Disagree 
 Disagree  
            Neutral  
              Agree  







2. As a medical professional what is your experience (observation) in the 
use of medicinal products that is produced in Nigeria or medicinal 
products that are manufactured in different countries? 
 
 Preference for the use of medicines that are produced abroad. 
 Usually medicinal products that are produced by Nigerian pharmaceutical 
companies. 
 Use of both at any time. 





a. What type of drug would you prefer to prescribe for your patients?  
 Drugs produced in Nigeria  
 Drugs produced Abroad  
 No preference 





b. What type of medicine do you prefer to use in your area of expertise for your patients.  
 Medicine produced in Nigeria 
 Medicine produced Abroad  
 No preference 











3. Do you think there are certain factors that can influence or impact  on 
the quality of medicinal product in Nigeria: 
 
Please tick the appropriate box: 
i. High cost of good quality drugs 
                   Strongly Disagree  
                   Disagree 
                   Neutral  
                   Agree  
                   Strongly Agree 
 
 
ii. Non – qualified / non proffesionals in drug production and distributions 
                   Strongly Disagree    
                   Disagree 
                   Neutral  
                  Agree  
                  Strongly Agree 
 
iii. Inadequate laws or poor enforcement of the existing drug quality control 
regulations 




 Strongly Agree 
 
 
iv. Inadequate drug distribution monitoring system 
 Strongly Disagree  
 Disagree  
 Neutral  
                        Agree  
                        Strongly Agree 
 
v. Demand exceeding supply 











4. Do you think drugs produced in Nigeria are of better quality than that 
produced abroad? 
 




5. Do you think the degree of fake drug distribution in Nigeria has 
reduced within the last ten years?  
 





6. As per your expertise – who are the distributors of Vaccine in your 
country? 
 WHO – World Health Organization   
  NAFDAC 
 






7. Do you think NAFDAC is improving quality control of  production and 
distribution of medicinal products in Nigeria? 
  
 Yes   








                                                 PHARMACISTS 
Please tick the appropriate box: 
1. What is your opinion about the quality of medicinal products in 
Nigeria? 
 






a. Do you agree or disagree wth the statement that medicinal products in Nigeria 
are low quality? 
 
Strongly Disagree 
 Disagree  
            Neutral  
              Agree  
            Strongly Agree 
 
b. Do you agree or disagree wth the statement that pharmaceutical companies 
based in Nigeria are producing and distributing low quality medicine? 
 
Strongly Disagree 
 Disagree  
            Neutral  
              Agree  





2. As a professional what is your experience / observation of your 
castomers/ consumers: What type of medicinal product  they are 
prefer: 
 
Please mark suitable box below: 
 Customers select medicines that are produced abroad. 
 Customers prefer medicinal products that are produced by Nigerian 
pharmaceutical companies. 
 Use of both at any time. 
 No preference 
 










3. Do you think there are certain factors that can influence or impact  
on the quality of medicinal product in Nigeria: 
 
Please tick the appropriate box: 
 
i. High cost of good quality drugs 
                   Strongly Disagree  
                   Disagree 
                   Neutral  
                   Agree  
                   Strongly Agree 
 
 
ii. Non – qualified / non proffesionals in drug production and distributions 
                   Strongly Disagree    
                   Disagree 
                   Neutral  
                  Agree  





iii. Inadequate laws or poor enforcement of the existing drug quality control regulations 




 Strongly Agree 
 
 
iv. Inadequate drug distribution monitoring system 
 Strongly Disagree  
 Disagree  
 Neutral  
                        Agree  
                        Strongly Agree 
 
 
v. Demand exceeding supply 













3. What type of medicinal products would you advise to your 
consumers / customers to purchase? 
 
Please tick the appropriate box: 
 
  Medicine produced in Nigeria  
             Medicine produced abroad  
             No preference 
 
 







4. Do you advise your consumers / customers to scratch and send the 
certification pin when you issue drugs to them?  
Yes   
No 
 
5. Do you think that medicine produced abroad have better quality than 
medicine produced in Nigeria. 
 
 Yes   
 No 
 
6. Do you think NAFDAC is improving quality control of  production 
and distribution of medicinal products in Nigeria? 
  
 Yes   


















                                                       SECTION B 
NAFDAC OFFICIALS 
1. Do you agree or disagree with the statement that production and 
distribution of drugs in Nigeria are of low quality ? 
Please tick the appropriate box: 
 
Strongly Disagree 
 Disagree  
            Neutral  
              Agree  
            Strongly Agree 
 
2. What is your opinion about major factors  that can influence or impact  on 
the quality of medicinal products in Nigeria: 
Please tick the appropriate box: 
 
i. High cost of good quality drugs 
                  Strongly Disagree  
                  Disagree 
                  Neutral  
                  Agree  
                  Strongly Agree 
 
 
ii. Non- professionals in drug business 
                  Strongly Disagree    
                  Disagree 
                  Neutral  
                  Agree  
                  Strongly Agree 
 
 
iii. Inadequate laws and poor enforcement of the existing procedures: 







iv. Inadequate drug distribution monitoring system 






v. Demand exceeding supply 











3. What measures have been taken by NAFDAC to control the production 
and distribution of low quality medicinal products in Nigeria. 





4. Do you agree or disagree that the fake drug production in Nigeria has 













                                                     SECTION B 
PROFESSIONALS WORKING IN THE PHARMACEUTICAL INDUSTRY 
 
Please tick the appropriate box: 
 
1. What is your opinion about the quality of medicinal products in 
Nigeria? 
 





a. Do you agree or disagree wth the statement that medicinal products in Nigeria 
are low quality? 
Strongly Disagree 
 Disagree  
            Neutral  
              Agree  
            Strongly Agree 
 
b. Do you agree or disagree wth the statement that pharmaceutical companies 
based in Nigeria are producing and distributing low quality medicine? 
 
Strongly Disagree 
 Disagree  
            Neutral  
              Agree  








c. What type of drug would you prefer to recommend for your consumers?  
 Drugs produced in Nigeria  
 Drugs produced Abroad  
 No preference 
 Or another product; please  specify   ___________________ 
 
 
d. What type of medicine do you prefer to use in your area of expertise: 
 Medicine produced in Nigeria 
 Medicine produced Abroad  
 No preference 





2. What is your opinion about major factors  that can influence or 
impact  on the quality of medicinal products in Nigeria: 
                    Please tick the appropriate box below: 
i. High cost of good quality drugs 
                   Strongly Disagree  
                   Disagree 
                   Neutral  
                   Agree  
                   Strongly Agree 
 
 
ii. Non – qualified / non proffesionals in drug production and 
distributions 
                   Strongly Disagree    
                   Disagree 
                   Neutral  
                  Agree  




iii. Inadequate enforcement of the existing drug quality control regulations 
 




 Strongly Agree 
 
 
iv. Inadequate drug distribution monitoring system 
 
 Strongly Disagree  
 Disagree  
 Neutral  
                        Agree  




v. Demand exceeding supply 
 












3. To what extent have your company adopted the following quality 
management practices? 
                    Please tick the appropriate box: 
 
i. Employee participation in the overall quality management.   
 
ii. Every sector of the company is involved in the quality management process of 





iii. Senior managers define the organisation’s quality objectives and ensure its 
continuous communication to the employees.  
 
 






4. Do your company ensure the distribution of drugs to only 
licensed distributors?                      






5. How often does NAFDAC inspect your drug production process  
Please tick the appropriate box: 
 
 Very Often 
  Often 
  Undecided  
  Seldom  








1. Do you agree or disagree with the statement that production and 
distribution of drugs in Nigeria are of low quality ? 
Please tick the appropriate box below: 
 
Strongly Disagree 
 Disagree  
            Neutral  
              Agree  
            Strongly Agree 
 
 
2. What is your opinion about major factors  that can influence or 
impact  on the quality of medicinal products in Nigeria: 
 
      Please tick the appropriate box: 
i. The high cost of good quality drugs 
                  Strongly Disagree  
                  Disagree 
                  Neutral  
                  Agree  
                  Strongly Agree 
 
ii. Non-health professionals in the drug business 
                  Strongly Disagree    
                  Disagree 
                  Neutral  
                  Agree  
                  Strongly Agree 
 
iii. Inadequate laws and poor enforcement of the existing ones  










iv. Loose control system  






v. Demand exceeding supply 












3. What type of drugs do you prefer to buy? 
      Please tick the appropriate box:  
Drugs produced in Nigeria   
Drugs produced abroad 
4. Do you think that drugs produced in Nigeria are of better quality 
than that produced abroad? 
                   Please tick the appropriate box:  
              Yes   
No 
5. Where do you prefer to purchase your drugs?  
      Please tick the appropriate box:  
Pharmacy stores 
Chemist stores   
Roadside stores 
 Or other, please  specify   ___________________ 
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6. Can you identify if your purchase drugs are fake or authentic? 
 





 If No Please specify _________________________________ 
 
_____________________________________________________ 
 
__________________________________ 
 
 
 
 
 
